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ABSTRACT 
 
Carbopol is crosslinked acrylic acid. Carbopol can be used in developing formulations for 
transdermal, oral, rectal use. It is forms strong gel in low concentration. Therefore, it can be used 
in low concentration in developing controlled release formulations. This increases the cost 
effectiveness and number of formulation options. In spite of its effectiveness, carbopol is one of 
the most efficient however underutilized polymer in oral controlled drug delivery system 
development. This is attributed to the difficulty in processing the carbopol. Carbopol has poor 
flow characteristics and stickiness. Objective of our research is to eliminate processing 
difficulties of carbopol using hot melt granulation process and to develop sustained release oral 
formulations of a basic (Propranolol HCl) and an acidic drug (Glipizide).  
Hot melt granulation was used to prepare free-flowing, directly compressible carbopol-
wax blends. Evaluation of granular characteristics of carbopol-wax blends indicated that changes 
in the granular characteristics is dependent on process variables such as granulation temperature, 
granulation time and mixing speed. At higher granulation temperature, the granulation process 
became sensitive to granulation time and mixing speed. Thus, for developing robust granulation 
process to prepare carbopol-wax blends, the granulation must be done with lower granulation 
temperatures.  
Carbopol is an acidic polymer and forms complex with basic drugs. Carbopol-basic drug 
complex has poor solubility. Hence oral controlled delivery system containing carbopol and 
basic drug, result in incomplete drug release. Water uptake and tablet erosion studies confirmed 
that incomplete drug release is a result of ionic complexation and absence of tablet erosion. 
Thus, by selecting appropriate carbopol grade, extent of ionic complexation was reduced and by 
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using soluble filler in the formulation, an USP compliant controlled release oral formulation of 
propranolol hydrochloride was developed. 
Controlled release properties of carbopol matrix containing Glipizide were evaluated. 
Formulations containing lactose as filler, either had long lag time or burst release based on the 
concentration of lactose in the formulation.  Formulations containing Avicel yielded tablets with 
high hardness and zero order drug release. The drug release pattern of Avicel based formulations 
was dependent on drug-polymer ratio. Release of Glipizide from Avicel based formulations was 
dependent on compression force. Bioequivalent formulation of Glipzide was prepared using 
carbopol-wax blend.  
Near infrared spectrophotometer was used to predict dissolution profiles of propranolol 
sustained release tablets non-destructively. Three different modeling algorithms were compared 
for their predictability. K-nearest neighbors algorithm (KNN) yielded models with better 
predictability compared to partial least squares algorithm and support vector machines algorithm. 
Model validation was performed using independent data set. Model validation confirmed that 
KNN models can non-destructively predict dissolution profiles of sustained release propranolol 
tablets prepared at two different compression forces.  
 v
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Chapter 1: Introduction 
 
“Patients don’t take drugs, they take dosage forms”.  
“All drugs are toxins”. 
If we put above sentences together, we will realize that we give toxins to patients using 
dosage forms. Sixty years ago, although many scientists agreed that all drugs (toxins) are useful 
in curing diseases, not many scientists realized the dosage forms can offer distinct advantages 
such as reducing toxicity, extending therapeutic efficiency of drugs etc. However, now all 
pharmaceutical scientists and patients agree that pharmaceutical dosage forms make distinct 
difference in patient health care.  
In last five decades, scientists have developed many types of delivery systems each with 
unique advantages. One of the oldest drug delivery systems is oral drug delivery systems. Oral 
drug delivery systems are popular far more than a century due to many distinct advantages such 
as ease of administration, palatability, ease of manufacturing, high patient compliance compared 
to parentral administration, no need for hospitalization etc.  
Oral delivery systems include tablets, capsules, and molded pills. Since most of the drugs 
are available as solids and the stability of drugs is high at solid state, solid oral drug delivery 
systems are the most popular category of oral drug delivery systems among pharmaceutical 
scientists who explore use of different delivery systems for patient use. However, oral drug 
delivery systems are not “cure for all” technique. Modifications in the design of delivery system 
may be required based on needs. Needs may be different for each case.  
One of the most profound needs is to maintain drug concentration in systemic circulation 
for longer period of time. This is one of the most desirable properties of an ideal drug delivery 
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system. For, it reduces the frequency of administration and reduces the toxic effects of the drug. 
This objective can be achieved by formulating the drug in controlled release dosage form. 
Although there are multiple ways of designing delivering controlled release dosage forms, oral 
controlled drug delivery is one of the most popular and oldest techniques available. There are 
different types of oral controlled drug delivery systems available. They differ in the methods of 
manufacture, components of the system, method of administration etc.  
One of the widely used classifications of oral controlled drug delivery systems involves 
use of mechanisms of drug release. This includes (i) dissolution controlled, (ii) diffusion 
controlled, (iii) ion exchange controlled, (iv) solvent controlled. Controlled release properties of 
oral drug delivery systems are imparted and optimized by selection of appropriate ingredients in 
the formulations. One of the most commonly used ingredients in formulation is a slowly 
dissolving gel forming polymer. Development and optimization of controlled drug release 
systems mandate understanding of gel forming polymers, their interactions with drugs and other 
matrix ingredients with different solubility, permeability, ionic characteristics etc. Some basic 
understanding of each type of oral controlled drug delivery system is discussed here: 
 
1.1. TYPES OF ORAL CONTROLLED DRUG DELIVERY SYSTEMS 
 
1.1.1. Dissolution controlled drug delivery systems 
These types of systems employ dissolution control of active drug as release mechanism. 
This is one of the simplest types of systems. There are two types of dissolution controlled 
systems. They are (i) encapsulated products, (ii) matrix products. 
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In the encapsulated products type, the active drug is coated with a slowly dissolving 
polymer or a wax. This coating controls the exposure of drug to the dissolution media. Since the 
availability of the dissolution media for dug dissolution is controlled, the release of the drug from 
coated particles is slow.  
 
1.1.2. Diffusion controlled systems 
Diffusion controlled systems employ control over drug diffusion from the device as 
opposed to the control over drug dissolution of dissolution controlled systems. Diffusion 
controlled systems are useful for drugs with poor solubility while dissolution controlled systems 
are useful for drugs with high solubility. There are two types of diffusion controlled systems. 
They are (i) reservoir devices, (ii) matrix devices. In reservoir devices, a drug core is surrounded 
by a polymeric membrane. In matrix devices, the active drug is dissolved or dispersed in 
polymeric matrix.  
There are differences in mechanism of release kinetics followed by reservoir and matrix 
devices. While the drug release from reservoir devices can be explained by Fick’s law, matrix 
devices follow Higuchi’s equation.  
 
1.1.3. Ion exchange resins 
Unlike dissolution and diffusion controlled systems, the mechanism of drug release from 
ion exchange resins is different and depends on the exchange of ions between the dissolution 
media and the availability of exchange sites of the resins. First, the drug is complexed with the 
ion exchange resin, by exposing the saturated drug solution to calculated quantities of ion 
exchange resins. Then this product is either suspended or encapsulated in capsules for 
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administration. Upon administration, the ions in the dissolution media (biological fluids in gastro 
intestinal tract) are exchanged. As a result, drug ions are replaced by the ions in the dissolution 
media. This replacement releases drug from ion exchange resins to biological fluids.  
 
1.1.4. Solvent controlled systems 
These systems employ control over solvent uptake of the system as opposed to 
controlling the dissolution or diffusion of the drug. Thus, these types of systems can be suitable 
for drugs wide differences in solubility. There are two mechanisms by which solvent controlled 
systems exercise control over the drug release. They are (i) osmosis, (ii) swelling. 
Osmotic controlled systems have three basic components: (i) semi-permeable membrane, 
(ii) osmogen, (iii) delivery orifice. Semi-permeable is generally made up of cellulose acetate. It 
has selective permeability. The semi permeable membrane is designed in such a way that only 
water can permeate into the device and drug can not diffuse out of the device. The core of the 
device is coated with the semi permeable membrane. The core contains the drug and osmogen. 
Osmotic agents increase the osmotic pressure created, due to the dissolution of drug, inside the 
device. At high osmotic pressure, the contents of core are released through the delivery orifice. 
By optimizing the thickness of semi-permeable membrane, concentration of osmogen, diameter 
of the delivery orifice the drug release can be programmed precisely. 
Next type of solvent controlled systems is swelling controlled system. Swelling 
controlled systems are one of the most extensively studied and utilized systems. This system 
consists of polymers that can swell in aqueous environment. Polymers that are used to prepare 
swelling controlled systems are generally called hydrogels. There are two types of hydrogels (i) 
water soluble, (ii) water insoluble. Both of these types absorb lot of (more than 100% of its 
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original weight) water and form gel like structure in aqueous media. The viscosity and the 
resistance to drug permeability of these gels formed in aqueous media contribute to hydrogel’s 
ability to control the drug release.  
There is another classification of hydrogels based on its origin. This classification 
includes three types (i) natural, (ii) semi-synthetic, (iii) synthetic. Examples of each category are 
i. Natural: gelatin, dextran, collagen, fibrin, chitosan, alginate. 
ii. Semi – Synthetic: hydroxy propyl methyl cellulose, hydroxy ethyl cellulose, hydroxy 
propyl cellulose, ethyl cellulose. 
iii. Synthetic: acrylic acid derivatives (Carbopol®, Eudragits®), hydroxy ethyl methacrylate, 
N-vinyl-2-pyrrolidone. 
 
1.2. HYDROGEL BASED ORAL CONTROLLED DRUG DELIVERY SYSTEMS 
As mentioned earlier, considerable attention is given to matrix controlled oral devices 
prepared using hydrogels because of their advantages. They are  
i. Ease in processing. Systems containing swellable polymers have excellent compressibility 
and flowability characteristics. These two are prerequisites for routine manufacturing of 
tablet dosage forms.  
ii. High drug loading. It is possible to develop systems with wide variety of drug loadings 
however with a significant control on the tablet size. This increases the formulation 
options. 
iii. Design flexibility. Single or combination of polymers can be used to formulate the system. 
Polymers with different characteristics can be combined in a system to achieve unique 
advantages of the system. 
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1.2.1. Mechanism of drug release from hydrogels 
As mentioned earlier, hydrogels can absorb large quantities of water. So, their release 
mechanism is completely different from hydrophobic polymeric systems that release drug 
through pore diffusion process. In general, one of the following three modes of drug release is 
observed in hydrogel based formulations 
i. Diffusion controlled. 
ii. Swelling controlled. 
iii. Chemically controlled. 
Diffusion controlled systems can be explained using Fick’s law with constant or variable 
diffusion coefficients.  
Swelling controlled release from hydrogels is observed when the drug release is faster 
than hydrogel swelling. Typically, polymers used in these systems exist in glassy and rubbery 
states. These states of polymer define the boundaries in the delivery system. Modeling of drug 
release from these systems involves these boundary conditions. Two types of boundaries are 
observed in swelling controlled system. They are erosion boundary and swelling boundary. 
Erosion boundary is observed between the swollen gel layer and the dissolution media. Swelling 
boundary is observed between ungelled core (glassy polymer) and gelled layer (rubbery 
polymer). Distance between erosion boundary and swelling boundary is thickness of gelled layer. 
Ungelled layer of the tablet is called glassy core. The drug release depends on the thickness, 
viscosity of gelled layer and its interaction with drug molecules.  
Chemically controlled release depends on chemical reaction within the matrix. For, the 
drug molecule is chemically attached to polymer chains. Thus, hydrolytic or enzymatic cleavage 
must set the drug free to be released. In some cases, surface or bulk erosion of polymers may aid 
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drug release. Although this approach of chemically attaching drugs to polymer is popular 
research area, due to the regulatory restrictions it lacks market potential. Scientists have shown 
chemical cross linking can yield controlled release formulations that can release drug for 
multiple years with constant release rate. However, Food and Drug Administration considers an 
established drug as new molecule after any chemical modifications. This poses threat to very 
existence of the drug in the market and may need multi million dollar investments to get this 
product approved.  
Understanding of drug release mechanisms from delivery system helps us to predict the 
extent of drug release based on the type of the system and polymers used to control the drug 
release. Modulation of drug release is possible only if the factors controlling the drug release are 
precisely understood. In an effort to understand the drug release mechanisms, many scientists 
have developed empirical and semi-empirical mathematical models explaining drug release. 
There are few processes associated with drug release from polymeric systems. As these 
processes determine the drug release, they are pivotal in understanding of the drug release 
characteristics of polymeric systems. These processes are (i) water uptake, (ii) polymer chain 
relaxation with volume expansion (swelling), (iii) drug diffusion, (iv) dissolution of polymer 
(erosion). In most cases, more than one of these processes takes place simultaneously.  This 
creates a complex scenario. As these processes are time dependent, changes in the drug release 
can not be predicted accurately using a single mathematical model. However, closest 
approximations can be made using an appropriate model. 
In general, diffusion, swelling and erosion are the important rate limiting mechanisms in 
most of the drug delivery systems. Diffusion can be explained using Fick’s law. With one-
dimensional transport assumption, valid simple mathematical models can explain the drug 
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release. This model is valid only for flat, planar devices. However, tablets are three dimensional 
powder compacts thus this simple model can not be used and may require complex mathematical 
models to explain/predict the drug release. Complexity in modeling such devices can be reduced 
by assuming constant diffusivity. However diffusivity is a function of water content of the 
system. Water content of the system changes with time invalidating the constant diffusivity 
assumption. Thus models based on constant diffusivity are less useful.  
Polymer dissolution adds one more dimension to the problem that is already complex. 
Polymer dissolution will change the boundary conditions that are basically defined for explaining 
diffusion. Thus moving boundary conditions must be accounted in modeling such systems. Drug 
solubility may be another variable that can change the drug release mechanism. Drug solubility 
is an important factor when systems containing poorly soluble drugs are modeled.  
In general, overall drug delivery process from swellable polymers e.g. HPMC, Carbopol 
can be described as follows. 
i. Water concentration gradients are formed at polymer-water interface. This results in 
imbibition of the water into the matrix. This process depends on the physical status of the 
system. In dry systems the diffusion coefficient is low, where as in swollen gels it is similar 
to that of pure water. Water acts as a plasticizer and reduces the glass transition 
temperature of the polymer. Once the concentration of water is high enough to reduce the 
glass transition temperature to the temperature of the system, the polymer chains undergo 
transition from glass to rubbery state. 
ii. Water imbibition causes polymer swelling and results in dimensional changes of the 
system. Geometric dimensions of the system increase as a result of swelling.  
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iii. Contact of water with the drug in the system aid the dissolution of the drug and the 
dissolved drug diffuses out of the system. 
iv. Continuous water penetration increases water content in the system. Increasing water 
content substantially increases the diffusion coefficient. 
v. Poorly soluble drugs don’t dissolve freely in the available water in the system. Thus, 
coexistence of dissolved and undissolved species of drug can be observed. However, non – 
dissolved drug does not diffuse out. 
vi. Systems containing high loading of freely soluble drugs undergo structural changes as drug 
diffuses out. As drug diffuses out the matrix becomes more porous and offers less 
resistance to the remaining drug in the matrix. 
vii. Depending on the polymer type, extent of cross linking, degree of substitution the polymer 
dissolves slowly or rapidly. If the entire drug is released before any significant reduction in 
polymer content due to its dissolution, then this phenomenon is less important.  
 
1.2.2. Empirical and semi-empirical mathematical models 
 
1.2.2.1. Higuchi equation 
In 1961, Higuchi published a mathematical equation to describe drug release from matrix 
systems [1]. Although it was valid for planar systems initially, it was later modified to include 
different geometries and matrix characteristics. Higuchi equation was derived under pseudo-
steady state assumptions and has less practical use when “real” controlled delivery system is 
modeled. The basic equation of Higuchi model is: 
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Mt/A = √ D (2Co-Cs)Cst                                                                                         (Eq. 1.1) 
 
Where Mt is the cumulative absolute amount of drug released at time t, A is the surface area of 
the controlled release device exposed to the release medium, D is the drug diffusivity in the 
polymer , Co is initial drug concentration and Cs is the solubility of the drug in the polymer. This 
equation can be written as: 
 
Mt/M∞ = K√t                                                                                                           (Eq. 1.2) 
 
Where M∞ is the absolute cumulative amount of the drug released at the infinite time (equal to 
the drug loading in the system at time t=0) and K is a constant for design variables of the system.  
Thus, drug release at any given time is proportional to the square root of the time. Most 
attractive feature of this Higuchi equation is its simplicity and applicability to many cases. 
However, we must be mindful of Higuchi equation when it is used. The assumptions are 
i. Initial drug concentration in the system is much higher than the solubility of the drug. This 
assumption forms basis for pseudo-steady state approach.  
ii. One dimensional diffusion forms basis of mathematical treatments used in the equation. 
Thus, equation is valid only if the edge effects must be minimal.  
iii. Particle size of the suspended drug must be much smaller than the thickness of the system. 
iv. Swelling and/or polymer dissolution must be negligible. 
v. Drug diffusivity remains constant throughout the drug release period. 
vi. Perfect sink conditions are maintained. 
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Evidently, these assumptions are invalid in most of the drug delivery systems. However, 
Higuchi equation can be used to get an abstract idea of underlying release mechanism. 
Simultaneous occurrence of many effects such as swelling, transition from glassy to rubbery 
state, polymer dissolution, water diffusion in and out of the system, drug diffusion out of the 
system may result in pseudo square root time kinetics. In general, proportionality between 
cumulative amount of drug released and square root of time is regarded as an indicator of 
diffusion controlled drug release.  
 
1.2.2.2. Power law 
Power law is a semi-empirical equation to describe the drug release from polymeric 
systems. 
 
Mt/M∞ = ktn                                                                                                             (Eq. 1.3) 
 
Mt is cumulative amount of drug released at time t, M∞ is cumulative amount of drug released at 
infinite time, k is release constant incorporating structural and geometric characteristics of the 
system, and n is the release exponent indicating the mechanism of drug release. 
Peppas and co-workers [2, 3] not only introduced this equation but also explained uses 
and cautioned about its limitation. Power law is generalization of two independent drug release 
mechanisms. They are Fickian diffusion and Case II transport [4, 5]. In most systems containing 
swellable polymers, the drug release is additive result of polymer relaxation and diffusion [6]. 
Thus, power law gets one step closer to “reality” compared to Higuchi equation.  
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Release exponent ‘n’ in the power law takes multiple values based on geometry of the 
system. By default the value of ‘n’ is 1. This indicates that drug release is independent of time, in 
other words, zero order drug release or case-II transport. In this case, water imbibition is the rate 
limiting step in the drug release. As described earlier, water can act as plasticizer and change the 
physical state of the polymeric system from glassy to rubbery state. These transitions not only 
cause volumetric expansion of the system but also increase the mobility of the drug molecules.  
When power law assumes 0.5 as the value of ‘n’ then it indicates diffusion controlled 
drug release, if the value of n=1.0 then it indicates swelling controlled drug release. If the values 
of ‘n’ are between 0.5 to 1, then it indicates combination of both diffusion and swelling 
mechanisms. This superimposition of both diffusion and swelling mechanisms is called 
anomalous transport. It must be remembered that these values are valid only for slab geometry. 
‘n’ values for spheres and cylinders [7, 8] are given in the Table 1.1. 
 
1.2.2.3. Other empirical and semi-empirical models 
Another mathematical model was developed by Peppas and Sahlin [9]. This is an 
extension of power law equation. It is 
 
Mt/M∞ = k1tm +k2t2m                                                                                                                                               (Eq. 1.4) 
 
Where k1, k2 and m are constants. First term in the right hand of the equation represents the 
contribution of fickian diffusion (F) to overall drug release and the second term represents 
relaxational contribution (R). R/F ratio can be calculated using following formula 
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Table 1.1. Release exponent values for devices of different geometry 
 
Release exponent (n) Release mechanism 
Slab Cylinder Sphere  
0.5 0.45 0.43 Fickian diffusion 
0.5<n<1 0.45<n<0.89 0.43<n<0.85 Anomalous transport 
1.0 0.89 0.85 Case-II transport 
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R/F = k2tm/k1                                                                                                            (Eq. 1.5) 
 
R/F ratio can be used to identify the dominant release mechanism at any given time during the 
drug release. This can help to modulate the release profiles based on appropriate release 
mechanisms.  
Thus far, this review of controlled drug delivery systems with emphasis on oral 
controlled drug delivery systems illustrated the mechanisms of drug release, materials used for 
preparation of swelling controlled oral controlled delivery systems. One of the most efficient 
however under utilized polymer that can be used to prepare oral controlled drug delivery systems 
is carbopol.  
 
1.3. ORAL CONTROLLED DRUG DELIVERY SYSTEMS BASED ON CARBOPOL 
Carbopol is polymers of acrylic acid crosslinked with allyl sucrose or allylpentaerythritol. 
Among multitude of polymers available in market, carbopol offers unique advantages when used 
in oral controlled release formulations [10]. They are 
i. Systems containing carbopol as their major release controlling polymer show linear drug 
release (zero order release kinetics) for drugs with wide differences in solubility and doses. 
ii. Carbopol is an excellent bioadhesive. Bioadhesivness of carbopol helps the drug delivery 
system by increasing the gastro intestinal transit time. Increase in gastro intestinal time 
improves the bioavailability and helps to achieve complete drug release from the dosage 
form.  
iii. Carbopol forms a strong gel at low concentrations. High gel strength helps to achieve 
desired drug release profiles with low polymer concentration. Usage at low concentrations 
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will increase cost benefits of delivery system, effective sustained release formulation can 
be designed with smaller size tablets and more formulation options will be available.  
iv. Carbopol is synthetic polymer. Being synthetic, carbopol provides consistency in drug 
release profiles.  
v. Carbopol has excellent compressibility. It forms hard tablets even with low compression 
forces. 
As mentioned earlier, carbopol is one of the under utilized polymers in oral controlled 
drug delivery system development. Its usage is less compared to other cellulose polymers. 
However, there are studies [11-22] showing effectiveness of carbopol alone and in combination 
with other polymers to develop sustained release tablet formulations.  
 
1.3.1. Properties of carbopol 
 
1.3.1.1. Physical and chemical properties of carbopol 
Carbopol is high molecular weight polymer. It is acrylic acid derivative prepared by 
chemical crosslinking with polyalkenyl alcohols or divinyl glycol. It is available as flocculated 
powders with average particle diameter of 0.2 micron. Surface static charge cause aggregation of 
submicron size particles. These particle aggregates can have particle size upto 2 to 7 microns.  
Essentially, each particle can be visualized as polymeric network containing polymer 
chains inter connected with multitude of cross links. Each polymer particle is capable forming 
strong gels when in contact with water and represents all properties of polymer. This unique 
property explains the efficiency of carbopol as controlled release polymer at significantly lower 
concentration compared to cellulose polymers. The polymer properties are controlled by degree 
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of crosslinking which is dependent on amount of cross linker used during its preparation. Precise 
control over the extent of crosslinking adds consistency in the property of polymers unlike 
natural or semi – synthetic polymers. Cross linked polymers are insoluble in water however 
swellable in water. Most commonly used cellulose polymers such as Methocel® and Klucel® 
are uncrosslinked, linear polymers. They are water soluble and control drug release by swelling 
and erosion. 
When in powder form with low water content (2 to 4%), the glass transition temperature 
of Carbopol is 105oC. However, the glass transition temperature drops dramatically when the 
polymer comes in contact with water as water is a good plasticizer for Carbopol. Plasticization of 
carbopol by water causes gyration of polymer chains. Radius of gyration continues to increase 
with time. Increase in radius of gyration, increases end-to-end distance of polymer chains, 
resulting in swelling of polymer. Carbopol can swell up to 1000 times its original volume and 
swelling is dependent on the pH of the aqueous media. Carbopol reaches its maximum swelling 
when pH of the environment is above its pKa of 6±0.5. 
 
1.3.1.2. Molecular weight of carbopol 
It is impossible to measure accurate molecular weight of carbopol because of its 
extensive crosslinking. All analytical methods used for molecular weight determination require 
solubility of polymer as the measurements are made in dilute polymer solutions. Extensive 
crosslinking of the polymer chains make carbopol water insoluble hence impossible to estimate 
its molecular weight using conventional methods. However, using stoichiometric and theoretical 
calculations, molecular weight of carbopol can be estimated. It is calculated to be 3.5 billion. 
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This high molecular weight is attributed to hundreds of polymer chains interconnected with cross 
links in a polymer molecule.  
In linear polymers molecular weight and viscosity of the polymers are important factors 
controlling the drug release. However, in cross linked polymers like carbopol, they are 
unimportant. Nevertheless, the extent of crosslinking is important release controlling factor. 
 
1.3.1.3. Carbopol grades and their properties 
Introduced in mid 1960, carbopol is available in various grades. These are carbopol 934P, 
carbopol 974P NF, carbopol 971P NF and carbopol 71G NF. Carbopol 934P was one of the 
earliest grades of carbopol introduced to pharmaceutical market. However, benzene was used in 
crosslinking process in the preparation of 934P. Following toxicological concerns of residual 
benzene in carbopol 934P, pharmaceutical grades prepared with ethyl acetate were introduced. 
These are Carbopol 974P NF, carbopol 971P NF and carbopol 71G NF. Letter “P” in the name 
of carbopol grade indicates that this particular grade is suitable for pharmaceutical use. Letter 
“G” in the carbopol name indicates that this particular grade is available in granular form. Unless 
specified, all pharmaceutical grade carbopols are available as powders. All pharmaceutical grade 
carbopols have strong binding characteristics making them suitable for direct compression 
formulations. However, powder grades must be used in lowest necessary concentration in direct 
compression formulation as they have poor flowability.  Nevertheless, granular grades have good 
flowability and can be used in high concentrations in direct compression formulations.  
Carbopol 974P and 934 P have similar rheological characteristics. In spite of their similar 
rheological characteristics, they show different release characteristics when used in the tablets at 
same concentrations.  Carbopol 934P provides near zero order release profile through out the 
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gastrointestinal tract, while carbopol 974P provides semi-enteric release profiles i.e., slow 
release in stomach and faster release in intestine. Analogically, based on their viscosity 
characteristics, carbopol 934P and carbopol 974P can be compared to mayonnaise and carbopol 
971P can be compared to honey. Carbopol 971P is less crosslinked than 974 P. Carbopol 971P 
provides slow but more linear release than 974P. Carbopol 71G is granular form of 971P. 
Carbopol 71G has no chemical additives and prepared using roller compaction of carbopol 971P. 
Carbopol 71G has better flow characteristics than Carbopol 971P. 
 
1.3.2. Drug release characteristics of carbopol matrix 
 
1.3.2.1. Mechanism of drug release from carbopol matrix 
Carbopol based matrix has stark contrast in drug release mechanism compared to matrix 
containing cellulose based polymers such as Hydroxy Propyl Methyl Cellulose (HPMC), 
Hydroxy Propyl Cellulose (HPC), Hydroxy Ethyl Cellulose (HEC) etc. Cellulose based polymers 
are water soluble linear polymers. They form gel layer on tablet surface upon hydration. 
Thickness, strength of the gel layer depends on molecular weight, polymer concentration and 
viscosity characteristics of gel layer. At higher polymer concentration, proximity of linear 
polymer chains increases probability of chain entanglement. Entangled polymer chains offer 
more resistance to drug release compared to individual polymer chains. Thus, drug release is 
inversely proportional to polymer concentration. Since cellulose based polymers are water 
soluble, swollen gel layer dissolves (erodes) away from the matrix. The extent of erosion 
depends on viscosity of the polymer which in turn depends on the molecular weight of the 
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polymer. Thus, polymer with higher molecular weight releases drug slower compared to its low 
molecular weight counterpart.  
Controlled release properties of carbopol marix are related to less extent with its 
molecular weight and viscosity and dependent on carbopol concentration in the matrix. 
Controlled release mechanism of carbopol matrix is dependent on extent of gellation and 
swelling. Extent of polymer swelling is dependent on degree of crosslinking and pH of the 
dissolution media. When in dry state, drug is entrapped in polymeric matrix in its glassy state. 
Upon contact with water, the glass transition temperature of polymer lowers below the external 
temperature turning the polymer from glassy state to rubbery state. In rubbery state, the mobility 
of polymer chains is high compared to that of polymer in its glassy state. However, chain 
entanglement due to increase in chain mobility is dependent on extent of cross linking. Carbopol, 
as described earlier, has individual polymer particles which are composed of polymer chains 
attached by crosslinks. Thus, each particle turns into gel in which the drug is dispersed. 
Crosslinks enhance ability of gel-particles to entrap the drug molecules.  
Carbopol hydrogels are water insoluble unlike cellulose hydrogels. Thus, carbopol gels 
don’t erode. However, they absorb lot of water and create osmotic pressure inside the gel. When 
fully hydrated, the osmotic pressure will break up the structure and shed off individual pieces of 
hydrogels. This unique property contributes carbopol’s ability to release drug in near zero order 
fashion for long time [23-31]. It is hypothesized that upon gelling the surface of the polymer 
particles has gel layer. When glassy polymer turns into rubbery, hydrogel particles are formed. 
Each hydrogel particle can entrap the drug and form a drug reservoir. It can be imagined that 
hydrogel particle having drug is surrounded by swollen gel layer. Since the drug concentration is 
high in the hydrogel core, the thermodynamic activity of the drug increases and releases the drug 
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from hydrogel. Swollen gel layer at surface of the hydrogel acts as rate controlling membrane 
thus helping to achieve linear drug release from hydrogels.  
Since drug release from carbopol matrix depends on its hydrogel structure, factors 
influencing hydration and swelling of carbopol hydrogel can influence the drug release. 
Hydration and swelling of carbopol is dependent on crosslink density, extent of chain 
entanglement and crystallinity of the polymer. Rate of swelling is dependent on pH of the 
medium. Carbopol is an acidic polymer. It swells faster in alkaline pH compared to acidic pH. 
Since each polymer particle is capable of forming hydrogel, the channels in the hydrogel is 
dependent on the concentration of polymer. Increase in polymer concentration will decrease the 
diameter of channels in the hydrogel and decrease the drug release. Thus, polymer concentration, 
extent of crosslinking, pH of the dissolution media can significantly influence the hydrogel 
properties hence drug release. 
As mentioned earlier, thermodynamic potential of the drug is the chief driving force for 
the drug diffusion from carbopol hydrogel. Thermodynamic potential of the drug is a function of 
its solubility. Drugs with poor solubility will have poor thermodynamic potential and may 
partition into the hydrophobic domains of the hydrogels. Acrylic backbone of carbopol forms 
hydrophobic domain of the system. Thus, incase of poorly soluble drugs, drug partitioning may 
support carbopol’s ability to control the drug release. Absence of matrix erosion provides 
stability for the carbopol matrix for longer period of time. Combination of these properties 
results in linear drug release profile of poorly soluble drugs from carbopol matrix. In contrast, 
cellulose based polymeric systems will show fickian release pattern with poorly soluble drugs. 
This is attributed to solubility of cellulose matrix. In case of highly water soluble drugs, fickian 
diffusion is observed with carbopol matrix. Although this behavior is similar to that of cellulose 
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polymer, it is not due to the solubility of the matrix. It is attributed to quick dissolution of the 
drug or drug partition in to aqueous, low viscosity regions of the carbopol gels. Carbopol grades 
with high crosslinkinks e.g. Carbopol 974P offer large interstitial spaces where water is filled. 
Thus highly soluble drugs can quickly dissolve in these water filled channels and diffuse out of 
the matrix. In contrast, carbopol with less crosslinks e.g. Carbopol 971P form hydrogel with 
more uniform gel structure and less extent of water filled channels. Therefore, carbopol 971P is 
more effective than carbopol 974P in controlling drug release of freely soluble drugs. This is 
attributed to less number of interstitial channels and more uniform gel structure. 
Compared to cellulose polymers, it is sometimes beneficial to use carbopol based systems 
for poorly soluble basic drugs. According to Henderson-hasselbach equation, the basic drugs 
have maximum solubility in acidic pH values. Thus, if cellulose polymers are used in 
formulating basic drugs, then acidic salts must be used in the formulation to solubilize the drug. 
Otherwise the drugs will precipitate in the tablet and will not be released to the fluids in GIT. 
However, carbopol is an acidic polymer. So, carbopol based sustained release matrix has acidic 
micro environment. Thus, it requires no acidic salt to maintain an environment to solubilize the 
drug.  
Carbopol based tablets show limited erosion at high (more than 10%) polymer 
concentration. This is attributed to entanglement of polymer chains resisting de-aggregation of 
polymeric matrix. Carbopol is water insoluble due to its extensive cross linking. Absence of 
matrix erosion and insolubility makes carbopol matrix very robust to wide differences in gastric 
motility, pH and fluid content in the gastro intestinal tract. Besides, tablets prepared using high 
compression forces are likely to have less interstitial space. This leads to reduction in number of 
channels for drug diffusion and result in decrease in drug release.  
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1.3.2.2. Crosslink density and drug release from carbopol matrix 
As discussed earlier, gel structure and drug characteristics are the most important factors 
that influence the drug release characteristics of carbopol matrix. Gel structure is dependent on 
the extent of crosslinking and differences in micro and macro viscosities of gel structure. 
Upon hydration, carbopol 971P, grade with low crosslink density, forms “fishnet” gel 
structure. Low crosslinking permits polymer chains to open up as there is less constraints on the 
polymer structure. As the polymer opens freely upon hydration, the interstitial spaces are 
virtually eliminated and uniform gel is formed. This implies that there is less difference in the 
viscosity between micro and macro viscosity regions of the gel. This homogenous gel structure 
offers high resistance to drug diffusion compared to grades with high degree of crosslinking. 
Thus, carbopol 971P may be more efficient at lower concentration compared to carbopol 974 P 
in controlling drug release.  
Carbopol 974P, grade with high crosslink density, forms gel with “fuzzyball” structure. 
High number of cross links constrains the polymer swelling upon hydration. Therefore, the 
polymer does not open up leading to high difference in the viscosities of the different regions in 
the carbopol gel. These regions are called micro and macro viscosity regions based on their 
viscosity. Micro viscosity region has gel with low viscosity and macro viscosity region has gel 
with high viscosity. The differences in the gel viscosity stems from the differences in the water 
content in different regions of the gel. In carbopol 974P, since the polymer chains don’t open up, 
they form gels with wide differences in viscosities of micro and macro viscosities.  
Thus, in essence, carbopol gels are non-homogenous. They have micro and macro 
viscosity regions. Differences in the viscosity of micro and macro viscosity regions depend on 
the degree of crosslinking. Carbopol grades with high cross link density show higher differences 
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in their viscosity between micro and macro viscosity regions while carbopol grades with low 
cross link density show lower difference in their viscosity between its micro and macro viscosity 
regions. The differences in the gel characteristics also imply that carbopol 974P forms rigid gel 
microparticles while carbopol 971P forms flexible gels when hydrated. Although carbopol 974P 
forms rigid gel particles, the drug release from carbopol 974P gels is higher compared to 
carbopol 934P and carbopol 971P. This is attributed to the higher number of channels present in 
their gel structure.  
In simulated gastric fluid, carbopol gels are not fully hydrated. Based on their controlled 
release properties in the desending order, the carbopol grades can be arranged as carbopol 
971P>carbopol 934P> carbopol 974P. In simulated intestinal fluid or in a media with pH > 6, the 
carbopol gels are fully hydrated. In fully hydrated states, based on their controlled release 
properties in the desending order, the carbopol grades can be arranged as carbopol 
971P>carbopol 934P> carbopol 974P. The differences in the controlled release properties among 
different carbopol grades are attributed to their gel structure, differences in the number of 
channels in the gels formed etc. Carbopol 974P gels form rigid gel particles with more number of 
particles upon full hydration. Thus, when drug dissolves in the dissolution media, rigidity of the 
gel particles resist drug diffusion into the gel particles. This leads to accumulation of drug 
particles in interstitial spaces between gel particles. As these interstitial spaces turn into water 
filled channels over time, it results in high drug release. Carbopol 971P gels form flexible gels 
with less number of channels. Thus, when drug dissolves they can diffuse into gel particles. The 
uniform gel viscosity and less number channels resist the drug diffusion out of the gels. 
Therefore, drug diffusion into the gel structure is the rate controlling factor in drug release from 
carbopol gels and it is dependent on extent of crosslinking.  
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1.3.2.3. Effect of drug solubility on drug release from carbopol matrix 
Mostly carbopol polymer shows extended release profiles when fully hydrated when 
loaded with drugs with moderate water solubility i.e., less than 100mg/ml). Nature of drug 
release profiles is dependent on the degree of crosslinking, water solubility of the drugs and pH 
of the dissolution medium. Table 1.2 summarizes the effect of these factors on the pattern of 
drug release 
In general, water soluble drugs exhibit square root time release kinetics in both simulated 
gastric fluid and simulated intestinal fluid in all three grades of carbopol. However, poorly water 
soluble drugs exhibit near zero order release profiles in carbopol 934P and carbopol 971P and 
they show semi-enteric (less amount of drug released in acid and more amount of drug released 
in phosphate buffer) profile in carbopol 974P. 
Highly water soluble drugs like norephedrine HCl [32] from carbopol matrix are released 
through partition. Thus, drug dissolution is the release controlling mechanisms in such cases. 
Once dissolved the drug partitions into low viscosity region in the microstructure and released 
through channels.  
Perez-Marcos et al [30, 31] compared the release mechanisms of carbopol matrix for 
drugs with different solubility. Highly water soluble drug, atenolol, exhibited square-root-of-time 
dependent drug release while poorly water soluble drug, furosemide, exhibited zero order 
release. Huang et al [33] studied the effect of drug solubility on carbopol 934P matrix. 
Theophylline, a poorly soluble drug, exhibited fickian diffusion in SGF. Water soluble drugs, 
such as chlorpheniramine maleate and sodium salicylate, exhibited fickian diffusion in SGF. 
These studies confirm the significant relationship between drug solubility and drug release 
pattern from carbopol based matrix systems.  
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Table 1.2. Relationship between carbopol grade and drug release mechanisms 
 
 
Highly water soluble drugs Poorly water soluble drugs 
Carbopol grade 
pH = 1.2 pH = 7.5 pH = 1.2 pH = 7.5 
934P NF Fickian Fickian Non-fickian/ Anomalous 
Anomalous/ 
Case II 
971P NF Fickian Fickian Non-fickian/ Anomalous 
Anomalous/ 
Case II 
974P Fickian Fickian Non-fickian/ Anomalous Fickian 
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It is postulated that if the barrier controlled mechanism is predominant than diffusion, 
then a zero order drug release pattern is observed in carbopol matrix. In cases where zero order 
or near zero order release is observed, hydrated polymer may act as physical barrier for drug 
diffusion or polymer relaxation could slower the drug release.  
 
1.3.2.4. Effect of pH on drug release 
Carbopol is weakly acidic polymer. The maximum swelling of the polymer is achieved in 
basic pH. Oral controlled release formulations first reside in stomach before reaching intestine 
where the pH is basic. Acidic stomach pH does not support carbopol gelling. Thus with most 
drugs fickian release pattern is observed in stomach pH. Basic intestinal pH supports complete 
swelling of carbopol as it causes ionization of carboxylic acid groups. Ionization of carboxylic 
acid groups in polymer chains result in repulsion of polymer chains which is manifested as 
polymer swelling.  
Upon complete hydration and swelling, carbopol polymers exhibit a special type of non-
fickian anomalous release with poorly soluble drugs. It is called case II or near zero order drug 
release. It is attributed to formation of gel barrier and gel micro particles in carbopol based 
matrix systems. This is called barrier controlled release mechanism. Upon hydration, gel micro 
particles trap the drug inside the particles. Surface gel layer act as barrier coating controlling the 
drug release. As the drug particles are solubilized, their thermodynamic potential migrate the 
solubilized drug to the surface gel barrier. Now, Surface gel barrier contains saturated drug 
solution and maintain the concentration gradient required for uniform drug release. Drug diffuses 
out from saturated gel barrier to channels in the micro viscosity regions of the carbopol matrix. 
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Since each gel micro particle can serve as drug reservoir, this process of uniform drug release 
adds up and results in zero order drug release from the matrix.  
F. Bulut-Oner et al [34] used isoniazid, a water soluble drug, with 30% carbopol 934P 
matrix to study the effect of pH on the drug release characteristics. While all drug was released 
in less than fifty minutes in SGF, the drug release was sustained for seven hours in SIF and 
sustained for five hours in distilled water. Thus, at neutral and near neutral pH boosts the 
efficiency of carbopol matrix to sustain the drug release. 
Study by A.M. Cooper et al [32] illustrate the effect of pH on the drug release with 
carbopol matrix is not without exceptions. Testing basic CNS compounds in HPMC and 
Carbopol 974P matrices, authors confirmed similar fickian diffusion type release profiles with 
carbopol matrix in both SGF and SIF. This implies that nature of drug plays critical role in drug 
release characteristics of carbopol matrix. Thus, whenever the effect of pH on the drug release 
from carbopol matrix is discussed, it must be done in context to the nature of drug.  
Another special case is carbopol matrix containing ionizable drugs. Carbopol is an 
anionic polymer. In basic pH, carboxylic acid groups of carbopol ionize and the gel fully 
hydrates. Basic drugs undergo complexation with anionic carbopol when both drug and carbopol 
are ionized. In most cases, the drug – carbopol complex has less solubility than the pure drug. 
This supports carbopol’s sustained release properties. Therefore, pH independent, zero order 
release profiles are observed for basic compounds in carbopol matrix. Carbopol has carboxylic 
groups to the extent of 62%. This makes basic drugs most vulnerable for complexation [35, 36]. 
Complexation not only provides pH independent drug release but also results in incomplete drug 
release. Thus, the formulation must be optimized for required release profile keeping the total 
amount of drug release in mind.  
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Complexation of basic drugs with carbopol in basic media is not a universal 
phenomenon. Complexation depends on following factors [37]: 
i. Shielding of basic groups in the drug molecule. If basic groups of the drug molecule are 
shielded by non-ionizing functional groups, then it will reduce the chances for 
complexation. 
ii. pKa of the drug molecule. Weakly basic drugs undergo complexation to less extent 
compared to strongly basic drugs. For example, Verapamil Hydrochloride has pKa of 9.04 
and Papaverine Hydrochloride has pKa of 6.8. In comparision, Verapamil Hydrochlorde 
undergoes complexation to high extent compared to Papaverine Hydrochloride. 
iii. pH of the media and microenvironment must support the complexation. For effective 
complexation, the drug and carbopol must be completely ionized. Extent of ionization of 
drugs depends on the pH of the medium. Most of the basic drugs exist in completely 
ionized state in acidic pH. However carbopol remains unionized in acidic pH. Maximum 
swelling and ionization of carbopol resins is reported to occur in pH 5 to 9. Thus, for 
formation of drug-carbopol complex, the drug must be in completely ionized state in the 
pH values 5 to 9. At these conditions, the swelling of carbopol resin is maximum thus 
exposing ionized carboxylic acid groups for complexation with drug molecules. For 
example, Propranolol hydrochloride is a basic drug with pKa of 9.5. At acidic pH 
proproanolol is completely ionized. At pH 4.5 carbopol starts to ionize and complex with 
the ionized drug. At pH 7.5, 97% of carbopol is ionized and 99% of propranolol is ionized. 
Thus, the Propranolol – Carbopol complex formation is high in intestinal pH rater than 
gastric pH.  
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iv. Orientation and spatial arrangement of carboxylic acid groups in hydrated polymer can 
influence the extent of complexation. For example, carbopol 934, 940 and 941 have similar 
carboxylic acid content. However amount of polymer required for the formation of 
saturated drug-polymer complex is significantly different. This implies orientation of 
carboxylic acid groups influence the extent of complexation. Orientation of carboxylic acid 
groups in hydrated polymer depends on the extent of cross linking. Carbopol grades with 
high degree of cross linking don’t “open up” upon hydration as the cross links constrain the 
uncoiling of the polymer chains. Thus, higher the cross linking less the chances for 
complexation.  
 
1.3.2.5. Bioadhesion characteristics and drug release 
Carbopol is an excellent bioadhesive. Bioadhesive nature of carbopol helps to increase 
the bioavailability of the drugs [38]. When incorporated in tablets, carbopol increases the gastro 
intestinal transit time. Increase in gastric intestinal time improves drug absorption by keeping the 
tablet in regions of gastro intestinal tract where the drug absorption is high. Use of carbopol as 
bioadhesive to sustain the gastric transit time and improve the efficiency of controlled release 
systems is one of the extensively studied topics [38-71].  
Y. Capan et al [72] showed that sustained release acetaminophen tablets containing 
carbopol 934P as release controlling polymer provided more uniform excretion rate than 
conventional controlled release tablets containing cellulose polymers as release controlling 
polymer. A similar enhancement in bioavailability was observed by K. Ciftci [73] with lithium 
carbonate, a sparingly soluble drug and using carbopol 934P as sustained release matrix. Hence, 
it appears that enhancement in bioavailability is not a drug specific phenomenon however more 
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general and can be attributed to carbopol’s ability to increase the gastro intestinal transit time.  In 
a following paper, to illustrate the effect of tablet excipients on the improvement of 
bioavailability with carbopol tablets, K. Ciftci [73] et al compared formulations containing water 
insoluble fillers (Dibasic calcium phosphate, mirocystalline cellulose) and water soluble fillers 
(lactose and dextrates). Formulations containing water insoluble fillers showed poor 
bioavailability than conventional formulations containing cellulose polymers while formulations 
containing water soluble fillers showed similar bioavailability compared to conventional 
formulation. However, in formulations containing water soluble fillers, peak height of urinary 
excretion curve was low and the time required to reach peak height is longer indicating the fact 
that side effects of the drug may be low with carbopol formulations containing water soluble 
fillers. This finding implies that enhancement in performance of drug delivery system can be 
observed not only by increase in drug bioavailability with carbopol based polymeric system but 
also decrease in side effects of the drugs. These effects are related to other excipients in the 
formulation. Thus, in carbopol based tablet formulation the excipients must be selected not only 
to achieve an optimum drug release profile but also to maximize therapeutic potential or to 
minimize the side effects of the drug.  
In vitro dissolution test can serve as an indicator for extent of urinary excretion of drug 
from carbopol based sustained release tablets. Perez Marcos [30] et al developed a correlation 
between in vitro dissolution and urinary excretion of atenolol tablets containing carbopol 934P as 
release controlling polymer. 
Bioadhesive property of carbopol makes it suitable excipient in buccoadhesive tablet 
formulations [41, 42, 56, 57, 59, 60, 74-81], vaginal formulations [48, 49, 71, 82-84], ocular 
formulations [64, 66, 85, 86]. In general, carbopol is blended with other controlled release 
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polymer to optimize the drug release profiles. For, although carbopol is a good sustained release 
polymer, the gel strength of carbopol is too strong to release drugs with poor solubility. 
Therefore, combination of carbopol and other soluble linear cellulosic polymers are used in 
buccoahesive formulations.  
 
1.3.2.6. Release kinetics 
As discussed earlier, peppas model explain the release mechanism involved in the drug 
release. The release exponent “n” in peppas equation, based on the geometry of the device, can 
be used to identify the release mechanism. Peppas equation can explain drug delivery systems 
with three different geometries i.e., slab, sphere and cylinder. Tablets prepared with flat faced 
punches can be considered as slabs. In systems with slab geometry, n=0.5 indicates fickian 
diffusion, 0.5<n<1 indicates non-fickian (anomalous) transport, n=1 indicates case II transport 
(zero order drug release/time independent), n>1 indicates super case II transport. In non-fickian 
type diffusion, rapid release rate is observed in the first phase of the dissolution then the release 
rate tails of with time. Combination of diffusion and polymer swelling can cause this type of 
anomalous transport. The release exponent values may differ based on type of carbopol used in 
the formulation, pH of the dissolution media, drug solubility etc. This implies the release 
mechanism is function of multiple factors and drug specific. Generally drug release from 
carbopol follows non-fickian release kinetics. However, drug solubility, pH of the dissolution 
media, ionic characteristics of the drug and other excipients in the formulations can significantly 
influence the drug release kinetics of carbopol matrix [37, 70, 87-93]. 
For example, poorly soluble theophylline was formulated in sustained release tablet 
formulation using carbopol 934P, the release exponent of the formulation in SGF was 0.73 and 
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in SIF it was 0.93. This implies, swelling was more predominant mechanism of drug release in 
SIF compared to SGF.  
 
1.3.2.7. Excipients in controlled release formulations 
Excipients used in the formulations containing carbopol as release controlling matrix can 
have significant impact on controlled release property of the matrix [23, 30, 94]. Carbopol is 
compatible with most of the commonly used excipients such as anhydrous lactose, hydrated 
lactose, dicalcium phosphate, talc, magnesium stearate and starch. Freely water soluble 
excipients such as sugars must be avoided. For, upon dissolution the osmotic pressure created by 
sugars can break the carbopol matrix. Lactose was a better excipient compared to 
microcrystalline cellulose and starch. Microcrystalline cellulose can absorb lot of water into the 
tablet effectively ruining carbopol’s ability to retard the water uptake. Thus, formulations 
containing microcrystalline cellulose will require more carbopol compared to formulations 
containing dicalcium phosphate or lactose. This will increase overall cost of the formulation. 
Y. Capan et al [95] compared the use of dibasic calcium phosphate, microcrystalline 
cellulose, lactose and dextrates as fillers in sustained release formulation of lithium carbonate. 
Tested for their controlled release properties, formulations showed no significant difference in 
their prolongation of drug release. However, a significant difference is observed between water 
soluble fillers and water insoluble fillers in the urinary excretion of the drug. Formulations 
containing water insoluble fillers (dicalcium phosphate, micro crystalline cellulose) showed 8% 
less in average total drug excretion compared to formulations containing water soluble fillers 
(lactose and dextrates). This implies that invitro differences in the release profile from carbopol 
matrix are not an indicator of the biological performance of the formulations.  
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Dicalcium phosphate, water insoluble filler, can prolong the dissolution times of carbopol 
matrix compared to other water insoluble and soluble fillers. This is attributed to its aqueous 
solubility and inability to absorb water unlike micro crystalline cellulose. It noteworthy to 
mention that carbopol matrix doesn’t dissolve or disintegrate upon ingestion. They 
“deaggregate” and become individual gel micro particles then eliminated from the body. Before 
being eliminated, the individual gel particles can control the drug release. Thus, unlike cellulose 
ethers, carbopol based system can control the drug release not only when it was in intact shape 
but also after deaggregation into gel particles. 
Sustained release carbopol tablets containing starch as filler had poor sustained release 
properties. Starch is water swellable thus tablet swelling is extremely high resulting in tablet 
disintegration.  
Carbopol can be processed with other excipients to prepare co-processed excipients [96-
98]. Such co-processed excipients were found to have superior bioadhesive and controlled 
release properties. In spite of research based evidence on advantages of preparing novel co-
processed excipient, no commercial product is available. 
  
1.3.2.8. Modifying release profiles in carbopol matrix 
Drug release rate from carbopol matrix can be modified by selection of appropriate 
polymer grade and co-excipient in the formulation. Appropriate carbopol grade must be selected 
based on the drug solubility and requirement on duration of drug release.  
Slow drug release kinetics can be achieved with carbopol 971P or carbopol 934P. In 
general, increasing the polymer concentration reduces the drug release. The effect of carbopol 
concentration on the drug release depends on the filler used in the formulation. Non-swellable, 
 34
insoluble filler like dicalcium phosphate can prolong the dissolution time. Non-swellable, water 
soluble filler like lactose can provide shorter dissolution time. Thus, fine tuning of dissolution 
rate can be achieved by selection of appropriate filler or by combining fillers in the formulation.  
 
1.3.2.9. Extrusion spheronization 
As described earlier, water is a good plasticizer for carbopol. Glass transition temperature 
of carbopol reduces below room temperature when carbopol comes in contact with water. This 
makes carbopol based formulations very water sensitive. In extrusion spheronization process, a 
wet mass is made using aqueous fluids (water or binder solution) and extruded then spheronized. 
In general extrusion spheronization formulations use 30 to 40% of water as wetting fluid for 
preparing wet mass. However, if the formulation contains carbopol, then use of water as wetting 
fluid is impossible. In such cases, salt solutions can be used as wetting fluids [99].. Salt solutions 
reduce tackiness of carbopol. Salt concentration in the solution must be optimized to minimize 
the tackiness. Calcium chloride salt solution is commonly used as wetting fluid for formulations 
containing carbopol.  Calcium chloride concentration is salt of choice as formulations prepared 
using calcium chloride salt solution yield pellets with superior roundness and smoothness. 
Caclium chloride reduces the tackiness by complexing with ionized carboxylic acid groups. 
Calcium ions are bivalent cations and it can complex with two carboxylic acid anions. This 
complex nullifies the tackiness of carbopol.  
Few studies report use of carbopol in melt extrusion formulations [46, 100]. However, in 
melt extrusion formulation carbopol is generally used with other excipients in small quantities to 
improve either bioadhesivness of the formulations or to improve the efficiency of the controlled 
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release polymer. Carbopol has versatility to be processed in melt extrusion formulations. In 
future, novel carbopol based formulations can be developed using melt extrusion technique.  
It is our objective to find a method that can improve the usage of carbopol in 
pharmaceutical industry. Once if such method is identified, it was also our interest to develop 
controlled release matrix formulations using carbopol as release controlling polymer. 
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Chapter 2: Evaluation of Granular Characteristics of Carbopol-Wax Blend 
 
2.1. INTRODUCTION 
In situ hot melt granulation technology [101] is one of the quickest and simplest 
techniques available to prepare sustained release matrix granules. In this technique a waxy 
material is used as binder. It is uniformly blended with the drug, polymer and filler before 
granulation. During granulation, temperature of the granulator is raised above the melting point 
of the wax. Upon melting waxes form a viscous, sticky solution in the granulator to which the 
powder particles in the blend adhere and form agglomerate. Owing to the high shear mixing 
action in the granulator, the agglomerate is broken into smaller granules. Thus, the granule 
formation, breaking and size growth happen simultaneously as the waxy binder melts. Thus, this 
process is difficult to model. However, there are many process and formulation variables that can 
influence the physical properties of granules obtained. The physical property of granules is 
influenced by particle size of the waxy binder, jacket temperature, mixing speed, binder 
concentration, granulator load etc. 
Carbopol is cross linked poly acrylic acid, commercially available as many grades based 
on its degree of crosslinking. Although there are reports on use of Carbopol in preparation of 
hydrophilic matrix systems for oral controlled drug delivery, there are many process difficulties 
in handling this polymer in industrial setting. Carbopol is commercially available as fine powder 
with particles containing mean diameter of 0.2 microns. Owing to its fine particulate nature and 
static charge development it generally forms aggregates and mean diameter of these aggregates 
is 8 to 15 microns. Carbopol does not flow well because of its fine particulate nature, low density 
and static charge development. Carbopol is very sticky and it sticks with any kind of surface. 
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Carbopol is also available in granular grades that have bigger mean particle diameter, faster flow. 
However, there are different problems with granular carbopol grades. They are: (i) Less 
efficency i.e., Efficiency of carbopol to control the drug release is higher when it is used as fine 
particles as fine particles can form more intact gel structure. (ii) Use of granular grade does not 
solve stickiness problem.  
Hot melt granulation of carbopol with waxes can improve its flow characteristics and 
reduce the stickiness of carbopol. Since hot melt granulation is an in situ granulation technique, 
the powder grade of carbpol can be used thus maximum efficiency of the polymer to control the 
drug release can be attained. In this section, the development of hot melt granulation technique 
for preparing carbopol granules with Gelucire 50/13 is presented. Gelucire 50/13 is blend of poly 
ethylene glycol esters of long chain fatty acids and available as waxy solid. Based on the 
literature on in situ hot melt granulation, it was hypothesized that process conditions significantly 
influence the physical properties of granules. It was our interest to evaluate the effect of jacket 
temperature, mixing speed and massing time on the physical characteristics of the granules. This 
will aid in the development of robust granulation technique for preparing carbopol granules 
using a waxy binder.  
 
2.2. MATERIALS AND METHODS 
 
2.2.1. Materials 
Our primary materials in this study were obtained from commercial sources. They were 
Carbopol 971P (Noveon, Cleveland, OH), Gelucire 50/13 (Gattefosse, Paramus, NJ). 
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2.2.2. Methods 
 
2.2.2.1. Preparation of carbopol-wax blend 
Carbopol-wax granules were prepared using in situ hot melt granulation. Sixteen batches 
were prepared using different process conditions. Process conditions for preparing the batches 
are given in Table 2.1. Batch size for all batches was 300 gms. Pre-weighed quantities of 
carbopol 971P and the waxy binder were added to the Robot Coupe® (Jackson, MS) high shear 
granulator. Granulator blade was operated in forward mode for mixing the contents prior to 
granulation. Mixing was done at 1500 rpm blade speed for 2 minutes. Following mixing, a 
circulating water bath was attached to granulator. Temperature of water bath was set according 
to the conditions required for each batch. Temperature of water jacket of the granulator was 
maintained constant throughout granulation as per conditions required for each batch. 
Temperature of water bath was monitored using an external digital thermometer by placing the 
temperature probe of the thermometer in the sleeve in the jacket. Granulation speed and time 
were also set according to the conditions required for each batch. Granulation was done for 
specified time as per specifications for each batch. After granulation, the granules were allowed 
to cool to room temperature by spreading them on metal trays.  
 
2.2.2.2. Bulk density evaluation 
Bulk density of the granules was evaluated using a 50 ml measuring cylinder and a 
balance. Initially the weight of the measuring cylinder was tarred. Then, the granules were 
poured into the measuring cylinder till the fill volume was 40 ml using a funnel. Then the weight 
of the measuring cylinder with granules was taken. This gives the weight of the granules.
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Table 2.1. Process conditions used for preparing carbopol–wax blends 
 
 
Batch code Granulation temperature (oC) 
Mixing speed 
(RPM) Mixing time (Min) 
B - 1 60 1000 1.5 
B - 2 60 1000 2 
B - 3 60 2000 1.5 
B - 4 60 2000 2 
B - 5 65 1000 1.5 
B - 6 65 1000 2 
B - 7 65 2000 1.5 
B - 8 65 2000 2 
B - 9 70 1000 1.5 
B - 10 70 1000 2 
B - 11 70 2000 1.5 
B - 12 70 2000 2 
B - 13 75 1000 1.5 
B - 14 75 1000 2 
B - 15 75 2000 1.5 
B - 16 75 2000 2 
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Bulk density of the granules was calculated using Eq. 2.1 and the bulk density of the 
formulations is presented in Table 2.2. 
 
Bulk density = Weight of granules/Volume of granules                                          (Eq 2.1) 
 
2.2.2.3. Granule size evaluation 
The particle size and size distribution of each material in the formulation were 
determined by the Gilsonic Autosiever (Gilson Company, Inc., Worthington, OH).  A series of 
sieves with varying mesh size number ranging from 20 to 200 were used in this study.  Prior to 
the experiment, each sieve was weighed and the initial weight was recorded.  Approximately ten 
grams of sample were then placed on the top sieve (20 mesh), which was closed by rubber gasket 
and spacer.  Stack of sieves was then placed onto the shaker and tightened.  The stack was 
mechanically shaken for a total time of 7 minutes.  This total time was divided into 3 parts, time 
A, B and C. Time A (60 seconds) was the time required to increase the speed from zero speed to 
the predetermined shaking speed, whereas time B, which was set for 5 minutes, was the time 
maintained at the maximum amplitude.  Time C (60 seconds) was the time required for the 
decrease of speed from the maximum amplitude to zero speed.  
Once the cycle is completed, the lock was loosened and the stack of sieves was removed 
from the shaker.  The final weight of each sieve and the retained sample on each sieve and the 
sieve was weighed again together and the weight was recorded and the percentage of material 
retained on each sieve was calculated. Sieve shaker used in this study uses both ultra sonic 
vibrations and mechanical agitation to segregate granules according to their size. Use of ultra 
sonic sound for granule size separation minimizes destruction of granules during the test. 
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Table 2.2. Physical characteristics of carbopol–wax blends 
 
 
Granule size distribution (%)* Batch 
code 
Bulk 
density* 
(gms/ml) Coarse Medium Fine 
Dynamic 
flow rate* 
(gms/sec) 
B – 1 0.276±0.02 4.34±2.11 19.75±1.79 75.91±0.28 8.14±0.51 
B – 2 0.376±0.05 8.81±1.23 28.50±0.91 62.69±2.39 13.60±0.41 
B – 3 0.315±0.02 6.97±1.50 18.72±1.55 74.32±1.56 16.15±0.59 
B – 4 0.326±0.05 26.68±0.82 44.42±0.59 28.89±1.13 13.26±0.98 
B – 5 0.313±0.03 2.95±0.35 18.14±1.25 78.91±0.53 16.62±0.52 
B – 6 0.414±0.03 13.06±2.61 32.13±2.85 54.82±2.75 19.64±0.59 
B – 7 0.380±0.02 6.37±2.09 22.61±1.82 71.03±0.40 20.35±1.49 
B – 8 0.374±0.04 54.59±2.96 37.19±2.09 8.23±2.77 12.43±0.59 
B – 9 0.442±0.04 11.24±0.14 35.15±0.51 53.61±1.60 14.90±0.94 
B – 10 0.429±0.02 46.61±1.33 44.02±1.10 9.37±2.71 13.42±0.67 
B – 11 0.394±0.06 32.99±1.68 45.43±1.22 21.58±2.84 14.11±0.47 
B – 13 0.511±0.05 15.16±0.23 36.14±0.10 48.70±2.68 23.40±1.17 
B – 14 0.429±0.09 61.39±1.83 33.58±0.49 5.03±2.59 13.29±0.48 
 
 
*indicates values presented in the table are average of three measurements. Average values are 
presented with standard deviation of three measurements.
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Based on the retaining of the granules, they were divided into three categories; (i) Coarse 
granules (percent weight of granules retained on no. 30 sieve), (ii) Medium size granules 
(percent weight of granules that pass through no. 30 sieve and retained on no. 60 sieve, (iii) Fine 
granules (percent weight of granules that pass through no. 60 sieve). Percent weight of coarse, 
medium size and fine granules is presented in Table 2.2. 
 
2.2.2.4. Dynamic flow rate evaluation 
Dynamic flow of the material was determined using a Hanson Flowdex (Hanson 
Research Corporation, Chatsworth, CA).  The device consists of a metal cylinder attached to a 
metal plate with an orifice at the bottom.  This orifice was closed or opened by the movable stage 
attached to the bottom of the plate.  Material was filled into the cylinder with the orifice closed.  
Approximately three fourth of cylinder was filled with the material.  Once filled, the movable 
stage blocking the orifice was removed from the bottom of the plate and the material was 
allowed to flow through the orifice onto a balance, which was connected to a computer.  The 
dynamic weight change of material that flows through the orifice and time in millisecond were 
recorded electronically using Software WinWedge® (TAL Technologies, Inc., Philadelphia, PA).  
The data obtained was plotted as the weight of the material versus time.  The flow rate was then 
determined as the slope of the linear regression of the plot. Dynamic flow rate of all formulations 
is presented in Table 2.2. 
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2.3. RESULTS AND DISCUSSION 
 
2.3.1. Study design 
Objective of the study was to evaluate the effect of mixing speed and massing time of 
granulation at different jacket temperatures. Asymmetrical factorial design (41 X 22) with four 
different jacket temperatures and two levels (low, high) of mixing speed and massing time was 
used in this study.   
 
2.3.2. Bulk density 
Effect of mixing speed and massing time on bulk density of the granules at different 
jacket temperature is depicted in Figure 2.1. At 60oC jacket temperature and 1000 rpm mixing 
speed, increasing the massing time to high level increased the bulk density of the granules by 
36.14%. However, at 60oC jacket temperature and 1000 rpm mixing speed, increasing the 
massing time to high level increased the bulk density by 3.42% and this increase is statistically 
insignificant (P>0.05). This implies that there is a limit of densification achieved at higher speeds 
and this limit is reached at low massing time. This could be attributed to the high shear force 
created at high mixing speed. At higher shear force, the size growth is faster compared to lower 
speeds. However, the granule size increases with no significant increase in density of the 
granules. This could be due to the formation of rubbery granules at higher speed. At 65oC jacket 
temperature and 1000 rpm mixing speed, increasing the massing time to high level increased the 
bulk density of the granules by 32.48%. This is less compared to the change in bulk density 
observed at 60oC in same mixing conditions. At 65oC jacket temperature and 2000 rpm mixing 
speed, increasing the massing time decreased the bulk density by 1.45%.  
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Figure 2.1. Effect of process conditions on bulk densities of formulations† 
 
† Each bar represents average of three measurements. Standard deviation of three measurements 
is presented as error bars.  
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  Although this change is statistically insignificant (P>0.05), it implies formation of 
rubbery granules at higher speed. Results indicate formation of rubbery is dependent on the 
mixing speed and temperature. This is further supported by granules prepared at 70oC and 75oC. 
At 70oC jacket temperature and 1000 rpm mixing speed, increase in bulk density was 20.69% 
(lower compared to similar conditions at 60oC and 65oC). At 75oC jacket temperature and 1000 
rpm mixing speed, increase in bulk density was 15.01%. This shows that formation of rubbery 
granules is dependent on the jacket temperature.   
At 70oC jacket temperature and 2000 rpm mixing speed, increasing the granulation time 
resulted in formation of rubbery mass. And, at 75oC jacket temperature and 2000 rpm mixing 
speed, rubbery mass was formed at low and high massing times. This clearly shows formation of 
rubbery granules/mass is dependent on jacket temperature and mixing speed. Based on jacket 
temperature and mixing speed settings, the massing time must be optimized to get granules of 
desired characteristics. For example, at high jacket temperature and high mixing speed, the 
massing time must be low to obtain discrete, free flowing granules.  
 
2.3.3. Granule size distribution 
Granule size distribution was non-normally distributed in most of the batches. Thus, 
geometric mean diameter could not be used for identifying the effect of process conditions on 
granule size growth. Since the size distribution was analyzed using sieves, three sieve cuts have 
been defined: coarse, moderate and fine. Granules retained on no. 30 sieve were considered 
coarse, granules that pass no. 30 sieve and retain on no. 60 sieve were considered acceptable and 
granules that pass through no. 60 sieve were considered fine. Granule size growth in insitu hot 
melt granulation is a complex process. It depends on particle size and size distribution of the 
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components of the blend and melting point of the wax, interaction between wax and other 
excipients etc.  
 
2.3.3.1. Coarse granules 
Effect of temperature and process conditions on the amount of coarse granules is depicted 
in Figure 2.2. At 60oC, when blade speed was 1000 rpm and the granulation time was increased 
from low to high, there was 102.98% increase in the amount of coarse granules. However, at 
60oC, when the blade speed was 2000 rpm and the granulation time was increased from low to 
high, there was 282.90% increase in the amount of coarse granules. This indicates that the size 
growth of the granules at a given jacket temperature is dependent on both mixing speed and 
massing time. The rate of size growth is faster at higher mixing speeds.  
A similar trend was observed at 65oC jacket temperature, however, the magnitude of the 
size growth was higher than one observed at 60oC. At 60oC jacket temperature and 1000 rpm 
blade speed, when the granulation time was increased from low to high, there was 342.69% 
increase in the amount of coarse granules. At 65oC jacket temperature and 1000 rpm blade speed, 
when granulation time was increased from low to high there was 757.30% increase in the amount 
of coarse granules. This indicates that the extent of coarse granules formed is dependent on 
mixing speed, massing time and jacket temperature. There is a significant interaction exist 
among these variables. Effect of mixing speed and mixing time on the extent of coarse granules 
formed will be higher at high jacket temperature. This can be attributed to the faster melting of 
wax at higher temperature. 
Similar trend was observed with 70oC and 75oC jacket temperatures with few exceptions. 
At 70oC, when mixing speed was 2000 rpm, increase in massing time turned the blend rubbery. 
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Figure 2.2. Effect of process conditions on the amount of coarse granules† 
 
† Each bar represents average of three measurements. Standard deviation of three measurements 
is presented as error bars. 
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This also implies that there is an interaction between Gelucire and carbopol 971P and this 
interaction results in formation of rubbery product. Formation of rubbery product in granulation 
is hastened by jacket temperature and mixing speed.  
 
2.3.3.2. Medium size granules 
Effect of temperature and process conditions on the amount of medium size granules is 
depicted in Figure 2.3. At 60oC jacket temperature and 1000 rpm mixing speed, increasing the 
massing time from low to high increased the amount of acceptable granules by 44.30%. 
However, at 60oC jacket temperature and 1000 rpm mixing speed, increasing the massing time 
from low to high increased the amount of acceptable granules by 137.35%. This indicates that 
formation of acceptable size granules depends on both processing speed and time. High mixing 
speed and longer mixing time at low jacket temperature yield more amounts of medium size 
granules.  
At 65oC jacket temperature and 1000 rpm mixing speed, increasing the massing time 
from low to high increased the amount of medium size granules by 77.08%. This is higher 
compared to similar processing conditions at 60oC. This implies at 1000 rpm, increasing jacket 
temperature and mixing time will yield higher amount of medium size granules. However, the 
trend was different at 2000 rpm. At 2000 rpm, increasing massing time increased the amount of 
medium size granules in the blend by 64.51%. This is significantly lower compared to similar 
conditions at 60oC where 137.35% increase was observed. At 70oC and 1000 rpm mixing speed, 
amount of medium size granules increased by 25.23%. However, at 75oC and 1000 rpm 
processing speed, amount of acceptable granules decreased by 7.08%.   
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Figure 2.3. Effect of process conditions on the amount of medium size granules† 
 
† Each bar represents average of three measurements. Standard deviation of three measurements 
is presented as error bars. 
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This implies: (i) size growth does not occur uniformly at all jacket temperatures, (ii) 
mixing speed and massing time have significant interaction with jacket temperature in 
determining the formation of amount of medium size granules. 
 
2.3.3.3. Fine granules 
Amount of fine granules is associated with the amount of coarse and acceptable granules 
formed and the amount of size reduction during the granulation. For, during in situ hot melt 
granulation, size growth and reduction take place simultaneously. Based on the processing 
conditions extent of size growth and reduction will differ.  
Effect of temperature and process conditions on the amount of fine granules is depicted in 
Figure 2.4. At 60oC jacket temperature and 1000 rpm mixing speed, increasing the massing time 
to high level decreased the amount of fine granules by 17.41%. However, at 60oC jacket 
temperature and implies that effect of jacket temperature on amount of fine granules is 
augmented by mixing speed. Aforementioned interpretations are supported by amount of fine 
granules formed at 70oC and 75oC at 1000 rpm mixing speed when mixing time was increased. 
At 1000 rpm, when mixing time was increased, while amount of fine granules decreased by 
82.52% at 70oC jacket temperature, amount of fine granules decreased by 89.67% at 75oC. 
Summarily, (i) amount of coarse, acceptable, fine granules formed is dependent on the 
jacket temperature, (ii) significant interaction exist between jacket temperature, mixing speed 
and mixing time. Generally, size growth is faster at higher temperatures and higher mixing 
speeds. And, size reduction was not observed at higher mixing speeds, (iii) at 70oC and 75oC 
jacket temperatures, the granulation process becomes sensitive to mixing speed and time. 
Increasing mixing time at 70oC and increasing mixing speed at 75oC will form rubbery mass.  
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Figure 2.4. Effect of process conditions on the amount of fine granules† 
 
† Each bar represents average of three measurements. Standard deviation of three measurements 
is presented as error bars. 
 52
2.3.4. Flow rate 
Flow rate of granules depends on granule size, size distribution and density of the 
granules. Effect of process conditions on the flow rate of granules is depicted in Figure 2.5. At 
60oC jacket temperature and 1000 rpm mixing speed, increase in massing time to high level 
increased the flow rate by 67.25%. However, at 60oC jacket temperature and 2000 rpm mixing 
speed, increase in massing time to high level decreased the flow rate by 18.06%. This could be 
attributed to the density of the granules. Since rubbery and low density granules are formed 
faster at higher speed, flow rate and granular density could be related. A similar trend was 
observed at 65oC jacket temperature. At 65oC jacket temperature and 1000 rpm mixing speed, 
increase in massing time to high level increased the flow rate by 18.12%, which is less compared 
to the increase observed in same conditions at 60oC. At 65oC jacket temperature and 2000 rpm 
mixing speed, the flow rate decreased by 38.85%. Batch prepared at 75oC jacket temperature 
with low mixing speed and low massing time had maximum flow rate (23.38 ± 1.16 gms/sec). 
This formulation had maximum density among all formulations (0.51 ± 0.02). This implies that 
flow rate and density are related and formation of low density, rubbery granules will result in 
reduction in flow rate of granules.  
 
2.4. CONCLUSIONS 
Free flowing carbopol granules can be prepared using hot melt granulation process. 
Gelucire 50/13 can be used as binder for granulating carbopol in hot melt granulation process.  
Physical properties of carbopol – wax granules were dependent on the process conditions used to 
prepare them in high shear granulator. Effect of mixing speed and mixing time on the physical 
properties of granules was dependent on the granulation temperature. Increase in granulation 
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Figure 2.5. Effect of process conditions on the dynamic flow rate of the granules† 
 
† Each bar represents average of three measurements. Standard deviation of three measurements 
is presented as error bars.  
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temperature turns the granulation process sensitive to mixing speed and mixing time. Free 
flowing, discrete carbopol–wax granules can be prepared in various process conditions. 
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Chapter 3: Formulation Development of Propranolol Hydrochloride 
 
3.1. INTRODUCTION  
Propranolol hydrochloride is a β-adrenergic blocking agent, i.e., a competitive inhibitor 
of the effects of catecholamines at β-adrenergic receptor sites. It is widely used in therapeutics 
for its antihypertensive, antiangorous and antiarrhythmic properties. Furthermore, it has a short 
elimination half-life of 3 h, which makes it a suitable candidate to be delivered at a controlled 
rate.  
Objective of this work is to develop sustained release matrix tablets of propranolol 
hydrochloride using carbopol – wax blends and to optimize the invitro drug release profiles 
according to USP criteria. The matrix tablets contained five components. They are 
i. Therapeutic agent: propranolol hydrochloride. 
ii. Release controlling polymer: carbopol 971P or carbopol 974P. 
iii. Binder: glyceryl mono stearate or gelucire 50/13. 
iv. Filler: dicalcium phosphate or lactose monohydrate. 
v. pH modifiers: sodium carbonate and glycine. 
Rationale for selection of aforementioned matrix component is given below. 
 
3.2. SELECTION OF MATRIX COMPONENTS  
 
3.2.1. Selection of release controlling polymer 
Carbopols have been reported in the literature for their potential use in oral controlled 
release delivery systems. This is because of carbopol’s ability to swell and form viscous gel in 
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aqueous environment. Carbopols can absorb lot of water and form gels and these gels are called 
hydrogels. When formulated with drugs, the carbopol hydrogels can entrap the drug molecules 
and control their release from the delivery system. Carbopols are available in various grades 
suitable for pharmaceutical use. Carbopol 971P and Carbopol 974P are the most commonly used 
grades used in controlled release oral formulations. Carbopol 971P is less cross linked than 
carbopol 974P. The release retardant property of carbopol is directly related to its concentration 
in the formulation. In general, drug release rate is inversely proportional to the carbopol 
concentration. It is reported that carbopol 971P is more effective than carbopol 974P in oral 
controlled release formulations. This is attributed to free uncoiling of polymer chains of carbopol 
971P and effective entrapment of drug molecules compared to carbopol 974P.  
Carbopol is an anionic polymer. Sixty two percent of the polymer is made up of carboxyl 
groups. Hence, it has high potential for interaction with basic drugs. This ionic interaction may 
boost carbopol’s controlled release potential i.e., may be effective in low concentrations 
compared to cellulose based polymers that have no interaction with basic drugs.  
In spite of its efficiency, carbopols are not commonly used in oral controlled delivery 
systems. As a result, complete understanding of mechanism of drug release with respect to 
dynamic swelling has not been developed. Hence, carbopol has been selected for this study. The 
objective of the study is to develop an USP (United States Pharmacopoeia) compliant 
formulation of propranolol hydrochloride and to optimize the drug release profiles based on the 
mechanism of drug release. 
  A literature survey showed no supporting literature for formulation development of 
propranolol hydrochloride controlled release tablets using carbopol – wax blends. Carbopol is 
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one of the most under utilized polymers in the pharmaceutical industry because of following 
reasons. 
i. Carbopol is commercially available as fluffy powder with average particle diameter of 0.2 
microns. Owing to its fine particulate nature, carbopols aggregate forming loose aggregates 
with average diameter of 8 to 30 microns. These loose aggregates have poor flow 
characteristics because of their low bulk density. 
ii. Carbopol is a sticky polymer. It is an excellent bioadhesive and it sticks to any kind of 
surface. This stickiness creates process difficulty.  
iii. Carbopol turns tacky in presence of water. Water is a good plasticizer for carbopol. When 
comes in contact with water, carbopol’s glass transition temperature lowers below room 
temperature. Therefore, most commonly used wet granulation process can not be used with 
formulations containing carbopol.  
Essentially, flow characteristics of carbopol must be improved and stickiness of the material 
must be reduced. Manufacturers of carbpol make granular grade of the material using roller 
compaction process. This granular grade has better flowability compared to powder grade. 
However, if granular grade of the carbopol is used in the formulation, then the efficiency of the 
polymer will be low. That is, more amount of polymer will be required to achieve controlled 
release properties similar to that of powder grade. Carbopol has unique gelling properties. Each 
carbopol particle has potential to form microgel and entrap the drug molecules. In granular 
grade, carbopol particles are compacted reducing individual polymer particle’s ability to entrap 
the drug molecule. Thus, more polymer is needed to compensate this loss of carbopol’s ability to 
control the drug release as polymer microgel. Hot melt granulation technique can solve this 
problem. Hot melt granulation is a granulation technique where no water is used for preparing 
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granules so polymer sticking is not a problem. Prior to granulation, intimate mixing of carbopol 
and the drug is achieved in high shear granulator. This blending provides proximity of carbopol 
particles to the drug particles. Therefore, less carbopol concentration is sufficient to control the 
drug release compared to using carbopol granules.  
 
3.2.2. Selection of therapeutic agent 
Propranolol hydrochloride was selected as model drug for this study for following 
reasons. 
i. Propranolol Hydrochloride has a high aqueous solubility. As a result, it is difficult to 
control its release from matrix tablets. However, if a matrix system is developed and the 
properties of system are understood, then it is comparatively easy to develop controlled 
drug delivery system for drugs with low solubility.  
ii. Propranolol Hydrochlorde is categorized as Class I drug in BCS classification. Class I 
drugs have high solubility and high permeability. It has uniform absorption throughout the 
gastro intestinal tract. These properties make propranolol hydrochloride as a suitable 
candidate for oral controlled release system. 
iii. Propranolol Hydrochloride is a basic drug (pKa = 9.5) and carbopol is an acidic polymer. 
At intestinal pH, 7.2, 99% of the drug exists in ionized form. At intestinal pH, carboxylic 
groups of carbopol are ionized and possess negative charges. Hence, there is potential 
interaction between positively charged amino groups of propranolol and negatively charged 
carboxylic acid groups. This ionic interaction could retard the drug release. Thus it is of 
interest to develop a delivery system which can release the drug completely, complying 
with USP standards.  
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3.2.3. Selection of pharmaceutical excipients 
 
3.2.3.1. Selection of binder 
In this study, besides developing a controlled drug delivery system for propranolol 
hydrochloride, the effect of two binders namely Glyeryl Mono Stearate and Gelucire 50/13 on 
the granular properties is investigated. 
Binder for the formulation development was selected based on favorable granulation 
characteristics. The evaluation criteria for granules are predefined and evaluated for formulations 
containing carbopol (10%) with binder (10%) and filler (80%). These formulations contained no 
drug as the interest was to develop general conclusions from the study rather than developing 
drug specific conclusions. The criteria for evaluation are 
i. Dynamic flow rate of the formulation must be more than 25 gms/ second. 
ii. Hardness of the tablets prepared from formulations using ¼” punches must be at least 4 kps 
at low (0.5 mT) and high (1 mT) compression forces. 
Two binders evaluated for their potential use in the formulation are Glyceryl Mono Stearate 
and Gelucire 50/13. Glyceryl Mono Stearate is a hydrophobic binder. Melting point of Glyceryl 
Mono Stearate is 56 to 58oC. It is available as flakes or free flowing powder. For the entire study, 
flakes were used. HLB value of Glyceryl Mono Stearate is 1.4 indicating hydrophobicity of the 
material. Glyeryl Mono Stearate was selected because of its hydrophobicity and its reported use 
in literature for preparing controlled release oral formulations. Being hydrophobic, Glyceryl 
mono stearate can retard the water influx into the delivery system. In addition, if used as binder 
in hot melt granulation, Glyceryl Mono Stearate can embed the drug particles and form a 
dispersion of drug particles in hydrophobic waxy matrix. This will hamper the availability of 
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drug particles to dissolution media and indirectly help carbopol’s ability to control the drug 
release.  
Another waxy binder evaluated in the study was Gelucire 50/13. Gelucire is blend of 
Glyceryl esters of fatty acids of poly ethylene glycol. Gelucires are commercially available with 
two number suffix, for example 50/13. The first number 50 denotes the melting point of the wax 
and the second number 13 denotes the HLB value of the wax. Gelucires are available in various 
melting points and HLB values. Gelucires with lower HLB values are hydrophobic and are 
recommended for controlled release applications. However, despite of the objective to develop 
controlled release product, Gelucire 50/13, a hydrophilic wax, is used. Gelucire 50/13 is selected 
to represent hydrophilic waxes as Glyceryl Mono Stearate represents hydrophobic waxes.  
 
3.2.3.2. Selection of fillers 
Two fillers are evaluated for their suitability to be used in the formulation. They are 
dicalcium Phosphate and Lactose monohydrate. Dicalcium phosphate is water insoluble filler 
and has no water swellability. Lactose monohydrate is water soluble filler.  
It is reported in literature that use of dicalcium phosphate boosts controlled release 
properties of drug delivery system. Being insoluble, dicalcium phosphate resists the water influx 
into the delivery system. Controlling water influx is the first step in developing an efficient drug 
delivery system. Efficient drug delivery system must not only control the water influx but also 
drug efflux. In addition, dicalcium phosphate has excellent flow and compression characteristics 
and low cost. Dicalcium phosphate is selected to represent a category of water insoluble, non-
swellable fillers. 
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Lactose monohydrate represents water soluble, non-swellable filler. Lactose is a natural 
disaccharide and prepared from milk. It is one of the most commonly used excipients in 
sustained and immediate release formulation. It is water soluble. It has solubility of 1g in 4.63 ml 
of water at room temperature.  
 
3.2.3.3. Selection of pH modifiers 
Sodium carbonate and glycine were selected as pH modifiers. Sodium carbonate 
represents category of strong alkaline salts and glycine represents category of weakly alkaline 
salts.  
As discussed earlier, carbopol is an anionic polymer with pH dependent gelling 
properties. In acidic pH (stomach) carbopol does not gel and in basic pH (intestine) carbopol 
forms strong gel. Since it does not gel, carbopol based matrix burst releases drug in acidic media 
and as it forms strong gel, carbopol based matrix releases drug incompletely in basic media. 
Thus, typically a burst release is observed following slow drug release in standard testing 
conditions (first 2 h in pH 1.2 and remaining time in pH 6.8). It was hypothesized that pH 
independent carbopol matrix can be developed by incorporating alkaline salts in the formulation. 
For comparative purposes, a strong alkaline salt e.g. Sodium carbonate and a weak alkaline salt 
e.g. glycine was selected to test this hypothesis. Following changes are expected in the matrix 
properties and drug release kinetics (Table 3.1).  
i. In acidic media, carbopol is likely to gel in presence of an alkaline salt. Normally, carbopol 
does not gel in acidic media and allows acid influx into the tablet. As acid penetrates the 
tablet, it reacts with the alkaline salt. This initiates acid-base reaction and result in increase 
in micro environment pH. If the increase in the pH of micro environment is high enough,
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Table 3.1. Comparison of changes in gelling and release characteristics 
 
 
Media No pH Modifier With pH modifer 
Acid 
(pH: 1.2) 
No gelling 
Burst release 
Surface gelling 
No Burst release 
Basic media 
(pH: 6.8) 
High gel stength 
Incomplete drug release 
Low gel stength 
Complete drug release 
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then carbopol gels and reduce the drug efflux from the tablet. This will control the burst 
release. 
ii. In basic media, presence of the salt in the tablet further increases micro environment pH. 
For example, when the pH of the dissolution media is 6.8 externally, inside the tablet the 
pH will be higher than 8 in presence of alkaline salt in the tablet. Carbopol gels have 
unique pH dependent strength. Gel strength of carbopol is at peak when the pH of the 
media is in the range of 5 to 9. pH values lower than 5 and pH values above 9 will reduce 
the gel strength. According to this, pH dependent gel properties, in presence of alkaline 
salts, carbopol matrix will de-aggregate in basic media (pH 6.8). This will help the matrix 
to achieve complete drug release.  
Formulation development of controlled release propranolol hydrochloride tablets was 
carried out in two steps.  
i. Selection of filler and binder for the formulation development 
ii. Development of sustained release formulations of propranolol hydrochloride 
a. Effect of alkali salts on the drug release  
b. Assessment of release mechanism 
c. Optimization of release profiles 
 
3.3. MATERIALS AND METHODS 
 
3.3.1. Materials 
Propranolol Hydrochloride, Glyceryl Mono Stearate (GMS) (Stepan, Northfield, IL), 
Gelucire 50/13 (Gattefosse, Paramus, NJ), Dicalcium phosphate Dihydrate (Ditab®) (Rhodia, 
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Cranbury, NJ), Lactose monohydrate spray dried (Foremost, Baraboo, WI), Carbopol 971P 
(Noveon, Cleveland, OH), Carbopol 974P (Noveon, Cleveland, OH), Sodium carbonate 
anhydrous (Fisher Chemicals, St. Louis, MO)., Glycine (Fisher Chemicals, St. Louis, MO). 
 
3.3.2. Methods 
 
3.3.2.1. Preparation of granules 
Granules for filler evaluation and preparation of sustained release tablets were prepared 
using hot melt granulation technique. Ingredients of formulations and composition of the 
formulations for selection of fillers are given in Table 3.2 and Table 3.3 respectively. Batch size 
of each formulation was 300 gms. Ingredients of the formulations except the waxy binder were 
blended in Robot Coupe® high shear granulator for 2 min at 1500 rpm.  
A circulating water batch was attached to jacketed walls of the granulator. Enough time 
was allowed for the temperature of the granulator to rise to 60oC and the temperature of the 
granulator was maintained at 60oC and the blade speed was 1500 rpm for the entire granulation 
process. Once the temperature of the granulator reached 60oC, the waxy binder was added to the 
granulator and the granulation was carried out for 2 minutes. After 2 minutes, the granulated 
mass was passed through # 16 sieve and the obtained granules were allowed to cool to room 
temperature. Granules were stored in double zip-lock® bags till compression. 
 
3.3.2.2. Preparation of tablets 
Granules, as prepared above, were compressed into tablets using rotary tablet punching 
machine. All batches were compressed with only one punch out of 18 punches of the machine. 
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Table 3.2. Ingredients of formulations for selection of fillers  
 
 
Batch code Wax Filler Carbopol 
FIL – 1 GMS Lactose No 
FIL – 2 GMS Ditab No 
FIL – 3 GMS Lactose Yes 
FIL – 4 GMS Ditab Yes 
FIL – 5 Gelucire 50/13 Lactose No 
FIL – 6 Gelucire 50/13 Ditab No 
FIL – 7 Gelucire 50/13 Lactose Yes 
FIL - 8 Gelucire 50/13 Ditab Yes 
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Table 3.3. Composition of formulations for selection of fillers  
 
 
Batch code Wax (%) Filler (%) Carbopol  (%) 
FIL – 1 10 90 0 
FIL – 2 10 90 0 
FIL – 3 10 80 10 
FIL – 4 10 80 10 
FIL – 5 10 90 0 
FIL – 6 10 90 0 
FIL – 7 10 80 10 
FIL - 8 10 80 10 
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Tablet weight of the all formulations was 320 mg and tablets were prepared using 5/16” deep-
concave punches. Tablet punching machine was operated with only one punch and remaining 
seventeen die cavities of the rotary punching machine were covered with blank dies. Machine 
was operated at 20 RPM for preparation of all formulations in the study. 
 
3.3.2.3. Bulk density evaluation 
Bulk density of the granules was evaluated using a 50 ml measuring cylinder and a 
balance. Initially the weight of the measuring cylinder was tarred. Then, the granules were 
poured into the measuring cylinder till the fill volume was 40 ml using a funnel. Then the weight 
of the measuring cylinder with granules was taken. This gives the weight of the granules. Bulk 
density of the granules was calculated using following formula and the bulk density of 
formulations is given in Table 3.4. 
 
Bulk density = Weight of granules/Volume of granules                                         (Eq. 3.1) 
 
3.3.2.4. Evaluation of dynamic flow rate 
Dynamic flow of the material was determined using a Hanson Flowdex® (Hanson 
Research Corporation, Chatsworth, CA).  The device consists of a metal cylinder attached to a 
metal plate with an orifice at the bottom.  This orifice was closed or opened by the movable stage 
attached to the bottom of the plate.  Material was filled into the cylinder with the orifice closed.  
Approximately three fourth of cylinder was filled with the material. Orifice was selected based 
on final dosage form weight. Granules were to be compressed as 100 mg tablets for evaluation of 
compressibility characteristics. Therefore 8 millimeter orifice was selected.  
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Table 3.4. Physical characteristics of formulations for filler selection†  
 
 
Batch code Bulk density (gms/ml) Flow rate (gms/sec) 
Tablet hardness 
at 0.5 mT (kps) 
Tablet hardness 
at 1 mT (kps) 
FIL – 1 0.529±0.02 15.98±0.51 2.32±0.33 2.38±0.16 
FIL – 2 0.865±0.04 26.14±0.78 3.35±0.15 3.60±0.11 
FIL – 3 0.561±0.02 25.33±0.81 2.98±0.13 3.30±0.11 
FIL – 4 1.136±0.02 44.29±1.25 4.97±0.14 5.27±0.69 
FIL – 5 0.531±0.02 10.54±0.56 1.98±0.23 2.13±0.08 
FIL – 6 0.917±0.05 23.54±0.67 4.23±0.29 4.37±0.32 
FIL – 7 0.503±0.03 0.00±0.00 3.97±0.40 4.40±0.60 
FIL - 8 1.011±0.03 19.87±0.78 3.47±0.42 3.72±0.52 
 
 
† indicates values presented in the table are average of three measurements. Average values are 
presented with standard deviation of three measurements. 
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Once filled, the movable stage blocking the orifice was removed from the bottom of the 
plate and the material was allowed to flow through the orifice onto a balance, which was 
connected to a computer.  The dynamic weight change of material that flows through the orifice 
and time in millisecond were recorded electronically using Software WinWedge®  (TAL 
Technologies, Inc., Philadelphia, PA).  The data obtained was plotted as the weight of the 
material versus time.  The flow rate was then determined as the slope of the linear regression of 
the plot and the dynamic flow rate of formulations for filler selection is given in Table 3.4. 
 
3.3.2.5. Evaluation of compressibility 
Compressibility of the granules was evaluated by estimating tablet hardness of tablets 
prepared from the granules. Granules, as prepared above, were compressed into tablets using 
rotary tablet punching machine. Tablet weight of the all formulations was 100 mg and tablets 
were prepared using 1/4” flat faced punches. Tablet punching machine was operated with only 
one punch and remaining seventeen die cavities of the rotary punching machine were covered 
with blank dies. Machine was operated at 20 RPM for compressibility evaluation study. Tablets 
were compressed in two compression forces i.e., 0.5 mT and 1 mT. After compression the tablets 
were stored in Ziplock® bags for one day before hardness evaluation. Tablet hardness was tested 
for randomly selected six tablets for each compression force. Hardness testing was done using 
Pharmatest® hardness tester and the hardness of tablets prepared at 0.5 mT and 1 mT 
compression force is given in Table 3.4.  
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3.3.2.6. Evaluation of in vitro drug release 
In vitro drug release characteristics of tablets were assessed using Paddle method (USP 
method II). Dissolution test was carried out in two different pH media to simulation gastro 
intestinal conditions. First 2 h, the dissolution test was carried out in 750 ml of pH 1.2 acidic 
media (0.1 N HCl). Then, 250 ml of 1 N Tribasic sodium phosphate solution was added to 
increase the pH of the dissolution media to 6.8. Required quantity of 1 N Sodium hydroxide 
solution was used to adjust the pH of the dissolution media if necessary after addition of 250 ml 
of 1N tribasic sodium phosphate solution.  Thus, dissolution was carried out in 250 ml of 0.1 N 
HCl for first 2 h, then 1000 ml of combination media with pH 6.8 for remaining 10 h. Total 
length of the dissolution test was 12 h.  
Drug release was measured using fiber optic UV probes with 5 mm inserts. Inserts are 
fixed at one end of the UV probe and the other end of the UV probe is connected to UV 
spectrophotometer with photo diode array detector. One end of the UV probe containing insert 
was immersed into the dissolution media during the dissolution study. Insert contains a reflecting 
mirror and the UV probe is designed in such a way that presence of insert forms an open 
chamber in which the drug solution will flow through during dissolution test. During dissolution 
test, at predetermined time intervals, the UV light from UV spectrophotometer is passed through 
UV probe. The UV light travels in the UV probe and transmits through the drug solution and 
reflected back to the detector by the reflecting surface in the insert. Based on the drug 
concentration in the solution contained in the open chamber, there are differences in the incident 
light and reflected light. UV absorbance of the drug solution was calculated from the differences 
in the intensity of incident light and reflected light. Reference drug absorbance was used to 
calculate the drug concentration in the solution. Calculation of drug concentration was based on 
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reference drug absorption taken at maximum wavelength of absorption for propranolol 
hydrochloride i.e., 278 nm. Volume of the dissolution media at the sampling time, drug loading 
were used to calculate the percent drug released. All these calculations were done in Indigo® 
software and the results were exported to Microsoft Excel®.   
 
3.3.2.7. Evaluation of mechanism of drug release 
The formulations' capacity for hydration (buffer medium uptake) and their extent of 
erosion were evaluated gravimetrically. This study was carried out similar to in vitro dissolution 
test i.e., for first 2 h the medium uptake was carried out in 0.1 N HCl then in 1000 ml of 
combination media containing 750 ml of 0.1 N HCl and 250 ml of 1 N tribasic sodium phosphate 
solution. For each time point, two tablets of each formulation were weighed individually and 
exposed to dissolution media. The test conditions such as paddle speed and the temperature were 
similar to that of dissolution test. At specific time points, tablets were removed from the medium, 
patted gently with a tissue paper, weighed, dried at 60 °C until constant weight was achieved. 
Percent weight gain (hydration) and % mass loss (erosion) were calculated according to the 
equations 3.1 and 3.2 using original, wet, and dry weight values obtained from the testing. 
 
% weight gain = 
Dryweight
DryweightWetweight −  X 100                                                    (Eq.3.1) 
 
% erosion = 
ightOriginalwe
weightdryremainingightOriginalwe )(−  X 100                                 (Eq.3.2) 
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3.4. RESULTS AND DISCUSSION 
 
3.4.1. Selection of fillers 
 
3.4.1.1. Bulk density 
Statistical analysis of effects of carbopol, type of wax and type of filler is given in Table 
3.5. Analysis indicates that change in wax type from Glyceryl Mono Stearate to Gelucire 50/13 
significantly reduced the bulk density of the granules obtained in the hot melt granulation. 
Changing filler in the formulation from lactose to Ditab significantly increased the bulk density 
of the granules. This could be attributed to the higher density of Ditab compared to that of 
lactose. Addition of carbopol in the formulations significantly increased the bulk density of the 
granules. This implies that carbopol can act as binder and enhance the densification of granules 
during hot melt granulation. This results in formation of higher density granules in presence of 
carbopol. 
No significant interaction was observed between effects of wax and fillers on the granule 
bulk density. This implies that effect of wax on the bulk densities of granules remains unchanged 
in lactose and Ditab. However, there is significant interaction observed between effects of wax 
and presence of carbopol in the formulation. This indicates, when Gelucire 50/13 was used as 
waxy binder, the increase in the granule bulk density is marginal. However, when Glyeryl Mono 
Stearate was used as waxy binder the increase in the granule bulk density is significant. If bulk 
densities of lactose and Ditab are compared, lactose has less density than Ditab. As densities of 
pure excipients are significantly different, the granules obtained from them will have 
significantly different bulk densities.  
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Table 3.5. Statistical analysis of physical characteristics  
 
 
Effect Bulk density (gms/sec) 
Flow rate 
(gms/sec) 
Tablet hardness 
at 0.4 mT (kps) 
Tablet hardness 
at 1 mT (kps) 
Intercept 0.76* 20.71* 3.41* 3.65* 
Wax (GMS - Gelucire) 0.02* 7.22* 0.00 -0.01 
Filler (Lactose - Ditab) -0.23* -7.75* -0.60* -0.59* 
Carbopol (Yes-No) -0.05* -1.66* -0.44* -0.53* 
Wax X Filler 0.00 0.47* -0.16 -0.20 
Wax X Carbopol -0.03* -5.21* -0.13 -0.12 
Filler X Carbopol 0.05* 1.96* -0.23 -0.27 
 
 
* indicates values are significant at P<0.05. 
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When lactose was used as filler in the formulations, addition of carbopol to the formulation had 
no significant influence on the granule bulk density. However, when Ditab was used as filler in 
the formulation, addition of carbopol in the formulation significantly increased the granule bulk 
density.  
 
3.4.1.2. Dynamic flow rate 
Statistical analysis of effect of carbopol, type of wax and type of filler on flow rate is 
given in Table 3.5. Statistical analysis indicates that change of wax type from Glyeryl Mono 
Stearate to Gelucire 50/13 significantly reduced the flow rate. Changing filler type from lactose 
to Ditab significantly increased the flow rate of the granules. Presence of carbopol in the 
formulation increased the flow rate significantly. Significant interaction existed between the 
effect of wax type and the presence of carbopol in the formulation. This indicates, when no 
carbopol was present in the formulation, change in wax type from Glyceryl Mono Stearate to 
Gelucire marginally changed the flow rate. However, when carbopol was present in the 
formulation, change in the waxy binder from Glyceryl Mono Stearate to Gelucire significantly 
reduced the flow rate. This confirms that effect of waxy binder on the granule flow rate is 
dependent on the presence of carbopol. Similarly, effect of filler on the flow rate of the granule is 
dependent on the presence of carbopol in the formulation.  
When lactose is used as filler, addition of carbopol did not significantly increase flow 
rate. However, when Ditab was used as filler, addition of carbopol significantly increased the 
flow rate. Thus, the effect of carbopol on the granule flow rate is dependent on the type of filler 
used in the formulation.  
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3.4.1.3. Compressibility 
Statistical analysis of the effect of Carbopol, type of wax and type of filler on the tablet 
hardness at low compression force (0.4 mT) is given in the Table 3.5. Statistical analysis 
indicates that change in the wax type had no significant influence on the tablet hardness at lower 
compression force. However, type of filler and presence of carbopol had significant influence on 
the tablet hardness. Change of filler from lactose to Ditab significantly increased the tablet 
hardness. Similarly, addition of carbopol in the formulation significantly increased the tablet 
hardness. Surprisingly, none of the interactions were significant. This implies, the main effects of 
individual factors remain unchanged in presence of other factors.  
Statistical analysis of the effect of carbopol, type of wax and type of filler on the tablet 
hardness at high compression force (1 mT) is given in Table 3.5. Statistical analysis indicates 
that the effect of wax type, filler type, presence of carbopol had similar influence on the tablet 
hardness (at high compression pressure) as their influence on tablet hardness at low compression 
pressure. That is, change of filler to Ditab in the formulation, increased the tablet hardness and 
addition of carbopol in the formulation increased the tablet hardness. None of the interactions 
among these factors were significant.  
It is noteworthy to mention, that the maximum hardness of each formulation was reached 
at low compression force and only marginal increase in the tablet hardness was observed when 
tablets were prepared at high compression pressure.  
In summary, fillers and binders were evaluated for their ability to flow well (at least 25 
gms/sec) and compress well (4 kps hardness). Based on the results, Dicalcium phosphate is 
selected as filler and Glyceryl Mono Stearate as waxy binder for formulation development.  
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3.4.2. Development of controlled release formulation 
 
3.4.2.1. Formulations containing sodium carbonate as release modifer 
Ingredients and composition of formulations for product development are presented in 
Table 3.6 and Table 3.7 respectively. Formulations PHP 1 to PHP 3 served as controls to 
evaluate the effect of pH modifer on the release profiles of formulations containing different 
concentrations of carbopol. Formulations PHP 4 to PHP 6 contained 10% sodium carbonate as 
release modifier. Comparison of the release profiles among different formulations was made by 
comparing the mean values of the drug release at 1 h, 3 h, 6 h and 12 h. These time points were 
selected as USP standard for sustained release dosage form of Propanolol Hydrochloride 
containing 80 mg of the active drug. USP recommends comparison of drug release at these time 
points. PHP 1 and PHP 2 formulations served as controls to estimate the effect of Carbopol on 
the drug release. PHP 1 contained all ingredients except carbopol and pH modifer. PHP 2 and 
PHP 3 contained all ingredients except pH modifer. Release profiles of PHP 1, PHP 2 and PHP 3 
are presented in Figure 3.1.  Student t-test comparing the amount of drug released between these 
two formulations was found to be significant at 1 h, 3 h, 6 h and 12 h.  This implies, addition of 
carbopol can significantly reduce the drug release and the effect of carbopol on the drug release 
is dependent on the carbopol concentration. That is, formulations contain low levels of carbopol 
release drug faster than formulations containing high levels of carbopol. Formulations PHP 4 and 
PHP 5 show the effect of 10% of sodium carbonate on the drug release profiles of formulations 
containing 10% and 5 % of carbopol respectively.  
Comparison of dissolution profiles formulations containing carbopol and carbopol with 
sodium carbonate is presented in Figure 3.2. 
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Table 3.6. Ingredients of formulations for product development  
 
 
Batch code Carbopol type Wax pH modifer Filler 
PHP – 1 No carbopol GMS No pH modifer Ditab 
PHP – 2 971 P GMS No pH modifer Ditab 
PHP - 3 971 P GMS No pH modifer Ditab 
PHP - 4 971 P GMS Sodium carbonate Ditab 
PHP – 5 971 P GMS Sodium carbonate Ditab 
PHP – 6 No carbopol GMS Sodium carbonate Ditab 
PHP – 7 971 P GMS Glycine Ditab 
PHP – 8 971 P GMS Glycine Ditab 
PHP – 9 No carbopol GMS Glycine Ditab 
PHP – 10 971 P GMS No pH modifer Lactose 
PHP – 11 974 P GMS No pH modifer Lactose 
PHP – 12 974 P GMS No pH modifer Ditab 
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Table 3.7. Composition of formulations for product development 
 
 
Batch code Carbopol (%) Wax (%) pH modifer (%) Filler (%) 
PHP – 1 0 10 0 65 
PHP – 2 10 10 0 55 
PHP - 3 5 10 0 60 
PHP - 4 10 10 10 45 
PHP – 5 5 10 10 50 
PHP – 6 0 10 10 55 
PHP – 7 10 10 10 45 
PHP – 8 5 10 10 50 
PHP – 9 0 10 10 55 
PHP – 10 10 10 0 55 
PHP – 11 10 10 0 55 
PHP – 12 10 10 0 55 
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Figure 3.1. Effect of carbopol on drug release† 
 
† Each data point represents average of three measurements. Standard deviation of three 
measurements is presented as error bars.
 80
 
0
10
20
30
40
50
60
70
80
0 2 4 6 8 10 12
Time (h)
C
um
. %
 D
ru
g 
R
el
ea
se
d
10% Carbopol
10% Carbopol+10% Sodium Carbonate
5% Carbopol
5% Carbopol+10% SodiumCarbonate
 
 
 
Figure 3.2. Effect of 10% sodium carbonate on dissolution profiles† 
 
† Each data point represents average of three measurements. Standard deviation of three 
measurements is presented as error bars.  
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If formulations PHP 2 and PHP 4 are compared, then the effect of adding 10% sodium carbonate 
to formulations containing 10% carbopol will be evident. Student t-test comparison of drug 
released at 1 h, 3 h, 6 h and 12 h revealed that the drug release was significantly different in these 
formulations at 1 h, 6 h and 12 h. Formulations containing sodium carbonate had less extent of 
drug release. This implies, that sodium carbonate can reduce the drug release from matrix tablets 
containing carbopol. A similar trend was observed in comparison between formulations PHP 3 
and PHP 6. This implies that Sodium carbonate can reduce the drug release from matrix tablets 
containing carbopol irrespective of carbopol’s concentration. However, the extent of effect of 
sodium carbonate on drug release is dependent on carbopol’s concentration. This implies that 
carbopol has more influence on the drug release than the sodium carbonate. Thus, sodium 
carbonate must always be used in conjunction with carbopol to effectively control the drug 
release. This fact is evident in dissolution profiles of formulation PHP 6. When compared against 
PHP 1, PHP 6 had no significant difference in the drug release at all data points. This implies, 
having only sodium carbonate in the tablets with no carbopol is an ineffective way of controlling 
the drug release. It is noteworthy to mention that addition of sodium carbonate has significantly 
reduced the drug release throughout the entire dissolution profile. This is in contrary to the 
expected outcome of the presence of sodium carbonate in the tablets. It was expected that when 
sodium carbonate is present in the tablet and the tablet is in dissolution media with pH 6.8, then 
the microenvironment pH within the tablet will be higher than pH 9. This will degenerate the 
matrix and release the drug faster. 
However, the results were different than expected. This implies that drug-carbopol 
complex formed at basic pH value is predominantly controlling the drug release. Moreover, in 
comparison among PHP1, PHP2 and PHP 3, it is evident that formulations containing carbopol 
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had incomplete drug release. This implies the formation of carbopol - propranolol hydrochloride 
complex results in incomplete drug release. 
  
3.4.2.2. Formulations containing glycine as release modifer 
Formulations PHP 7 to PHP 9 contained glycine as release modifier. Comparison of the 
release profiles among different formulations were made by comparing the mean values of the 
drug release at 1 h, 3 h, 6 h and 12 h. Formulations PHP 7 and PHP 8 shows the effect of 10% of 
glycine on the drug release profiles of tablets containing 10% and 5 % of carbopol respectively. 
Dissolution profiles of PHP 7 and PHP 8 with their control formulations containing similar 
concentration of carbopol are presented in Figure 3.3. If formulations PHP 2 and PHP 7 are 
compared, then the effect of adding 10% glycine to formulations containing 10% carbopol will 
be evident. Student t-test comparison of drug released at 1 h, 3 h, 6 h and 12 h revealed that the 
differences in the drug release were statistically insignificant at all aforementioned time points.  
This implies that glycine can not reduce the drug release from matrix tablets containing 
carbopol at 10% concentration. A similar trend was observed in comparison between 
formulations PHP 3 and PHP 8. This implies that glycine can not reduce the drug release from 
matrix tablets containing carbopol and this effect is similar in low (5%) and high (10%) carbopol 
concentration. These comparisons illustrate that glycine is an ineffective release modifier at 10% 
concentration.
 
3.4.2.3. Evaluation of mechanism of drug release 
Water absorption and erosion profile of formulations containing no carbopol (control), 10% 
carbopol, 10% carbopol with 10% sodium carbonate and 10% carbopol with 10% glycine are 
presented in Figure 3.4.  
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Figure 3.3. Effect of 10% glycine on dissolution profiles† 
 
† Each data point represents average of three measurements. Standard deviation of three 
measurements is presented as error bars.  
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Figure 3.4. Water absorption profile of formulations 
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Formulation containing no carbopol had almost constant amount of water in the tablet 
throughout the testing period. This formulation was made with only waxy binder. Literature 
reports that formulations made with waxy materials release drug through pore diffusion. Pore 
diffusion is concentration driven drug diffusion process in which drug is released through pores 
in the matrix. Pore diffusion is not dependent on the water uptake of the matrix. This is evident 
from the water absorption profile of tablet prepared with waxy binder.  
Formulation containing 10% carbopol had significant increase in water uptake till 8 h 
then the increase was marginal. This can be attributed to the presence of carbopol in the tablet. 
Carbpol is hydrophilic, swelling polymer. Matrix tablets containing such polymers continue to 
absorb dissolution media and this absorption depends on gel layer thickness, geometrical extent 
of swelling, solubility of the matrix components. If there is no interaction between drug and 
other components of the matrix, then the drug release must chiefly be dependent on the extent of 
water uptake of the matrix. Formulation containing 10% carbopol and 10% sodium carbonate 
had higher water uptake than formulation containing only carbopol. This could be because of the 
osmotic gradient created due to the dissolution of sodium carbonate in the tablet and the 
relaxation of polymeric chains due to presence of a salt that can induce ionization of polymeric 
chains.  
A similar trend in water absorption was observed in formulation containing 10% carbopol 
and 10% glycine, although the extent of water absorption was less than that of formulation 
containing sodium carbonate.This implies alkalinity of the salt has some relationship with extent 
of water absorption i.e., strong alkaline salts can induce the higher water absorption of the 
matrix. Thus, based on the effect of water absorption on the drug release, the water absorption of 
the matrix system can be modulated by adjusting alkalinity of the salts. Unexpectedly, the extent 
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of media absorption at the end of 2 h remained virtually same in all four formulations. 
Supposedly, the formulations containing alkaline salts were expected to have less acid uptake as 
the matrix is expected to gel due to change in microenvironment pH inside the tablet.  
Erosion profiles of aforementioned formulations are given in Figure 3.5. This Figure 3.5 
reveals that the extent of erosion of all formulations was similar. This was unexpected. 
Formulations containing alkali salts were expected to have higher extent of matrix erosion due to 
the expected higher microenvironment pH.  
Water absorption and erosion studies reveal two important facts. They are: First, alkali 
concentration used in the formulations was insufficient to reduce the acid uptake into the tablets. 
Second, alkali concentration used in the formulation was insufficient to induce the matrix erosion 
in pH 6.8.  
Relationship between the %water uptake and % erosion with %cumulative drug released 
respectively is presented in Figure 3.6 and Figure 3.7. Figure 3.6 showing relationship between 
% water uptake and %drug released reveals a positive slope in formulations containing carbopol 
and carbopol with alkai salts. This implies the drug release is related to % water uptake only less 
extent. Figure 3.7 showing relationship between % erosion and % drug released illustrates no 
relationship between matrix erosion and drug release. These plots confirm that the drug release is 
related to % water uptake to less degree and has no relationship with % erosion. Absence of 
matrix erosion can be attributed to incomplete drug release in formulations containing carbopol. 
Since the drug release is not significantly dependent on the %water uptake and % 
erosion, the main mechanism by which the drug release is controlled is ionic interaction between 
drug and carbopol. 
Thus, combining these results, to achieve complete drug release from carbopol matrix the 
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Figure 3.5. Erosion profiles of formulations 
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Figure 3.6. Relationship between water absorption and dissolution profiles 
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Figure 3.7. Relationship between erosion and dissolution profiles 
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grade of carbopol selected must have less chance to form complex with the drug. For example, 
carbopol 974, a grade with higher crosslink density, may be selected. Excipient in the 
formulation must support matrix erosion. This will counterbalance the effects of ionic 
complexation. All aforementioned formulations contained Ditab as filler. Ditab is water 
insoluble. It can be replaced with Lactose Monohydrate, water soluble filler.  
 
3.4.2.4. Formulations with lactose filler 
Ditab, the insoluble filler, was replaced with lactose monohydrate to achieve complete 
drug release while keeping the acidic drug release in control. Complete drug release can also be 
achieved by reducing the polymer concentration in the formulation. However, if the polymer 
concentration is reduced the duration of drug release will be shorter and the drug release in acid 
will be higher. This is undesirable to develop a formulation that complies with USP standards. 
Comparison of dissolution profiles of formulations containing Ditab as filler and lactose 
monohydrate as filler is presented in Figure 3.8. The comparison reveals, change in the filler 
from Ditab, an insoluble filler, to lactose monohydrate, a soluble filler has increased the drug 
release. The amount of drug released at 12 h was 68.43% in lactose monohydrate based 
formulations and this is significantly higher compared to 12 h release of 56.35% in Ditab based 
formulations with carbopol 971P as release controlling polymer. However, the USP compliant 
formulations must have 12 h drug release of not less than 80%. Thus, change in filler type to 
filler with higher solubility failed to yield the USP compliant formulation. 
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Figure 3.8. Effect of fillers on formulations containing carbopol 971P† 
 
† Each data point represents average of three measurements. Standard deviation of three 
measurements is presented as error bars. 
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3.4.2.5. Formulations containing carbopol 974P as release controlling polymer 
In the second step, the type of carbopol, release controlling polymer, was changed. In all 
aforementioned formulations, carbopol 971 P was used as release controlling polymer. Carbopol 
971 P is less crosslinked compared to carbopol 974P. Hydrogels formed from carbopol 971P has 
“fishnet” structure while the hydrogels formed from carbopol 974P has “fuzzball” structure. 
Polymer chains of hydrogels with “fishnet” structure have more mobility compared to the 
hydrogels of “fuzz ball” structure. Free mobility of polymer chains increases the probability of 
complexation between ionized polymer and the drug molecule. Thus, polymers with less 
crosslinks will impede the drug release to higher extent compared to polymers with high  
crosslinks. In formulation containing lactose monohydrate as filler and carbopol 971P as release 
controlling polymer the change was made. Carbopol 971P was replaced by carbopol 974P, a 
highly crosslinked grade of carbopol. Comparison of release profiles of formulations containing 
carbopol 971P and carbopol 974P is given in Figure 3.9. The Figure 3.9 clearly illustrates the 
complete drug release was achieved at the end of the dissolution. Comparison between the USP 
standards and dissolution profile of formulation containing lactose monohydrate as filler and 
carbopol 974P as release controlling polymer is given in Table 3.8. 
Although the USP compliant sustained release (SR) formulation was developed by 
combining highly cross linked grade of carbopol and soluble filler, it is not clear the final result 
is due to change in the carbopol grade or due to the change in the filler solubility. 
Thus, one more formulation was prepared using carbopol 974P as release controlling 
polymer however using dicalcium phosphate, water insoluble filler, as filler in the formulation. It 
was hypothesized that the complete drug release is due to the replacement of carbopol 971P by 
carbopol 974P then the change in filler must still a formulation that can release the drug 
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Figure 3.9. Effect of carbopol grade on dissolution profiles†  
 
† Each data point represents average of three measurements. Standard deviation of three 
measurements is presented as error bars. 
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Table 3.8. Comparison between optimized formulation and USP specifications  
 
 
Time USP requirement (80 mg SR tablet) 
Formulation with 10% 974P 
with lactose 
1 h Less than 20% 20.21±2.36% 
3 h 20-45% 40.71±2.84% 
6 h 45-60% 58.28±2.75% 
12 h Not less than 80% 96.79±3.67% 
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completely at the end of 12 h. Otherwise, the complete drug release is attributed to both 
solubility of filler and reduction in the extent of complexation between drug and carbopol. The 
formulation containing dicalcium phosphate as tablet filler did not yield complete drug release at 
the end of 12 h (58.96% drug release at 12 h). Therefore, it is confirmed that complete drug 
release is an effect of water solubility of the filler and reduction in the complexation of drug with 
carbopol.  
 
3.5. CONCLUSION  
Sustained release matrix tablets of propranolol hydrochloride can be developed using 
carbopol – wax blends. Mechanistic studies confirmed insignificant relationship between water 
absorption profiles and drug release profiles from formulations containing carbopol 971P as 
release controlling polymer. Little or no matrix erosion contributed to incomplete drug release 
from tablets containing carbopol 971P. Absence of matrix erosion and high degree of 
complexation resulted in incomplete drug release in formulations containing carbopol 971P as 
release controlling polymer. Sustained release formulation showing USP compliant drug release 
profiles was prepared using appropriate carbopol grade (carbopol 974 P) and filler (lactose 
monohydrate). Thus, selection of appropriate carbopol grade and soluble filler were pivotal in 
developing USP compliant formulation of propranolol hydrochloride.  
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Chapter 4: Formulation Development of Glipizide 
 
4.1. INTRODUCTION 
Type 2 diabetes is one of the most prevalent diseases in the modern world. Diabetes is 
currently the fourth leading cause of death by disease in the United States. Type 2 diabetes 
represents 98% of all diabetes among patients older than 45 years of age.  
There are two widely accepted hypotheses about origin of type 2 diabetes. First one is 
related to insufficient insulin secretion from beta cells. The second hypothesis is related to 
insulin resistance in the peripheral tissues. The beta cells initially compensate the normal glucose 
metabolism by increasing insulin secretion. However, when the demand for insulin exceeds the 
ability of beta cells to compensate, it leads to pancreatic exhaustion.  
As first line of defense for diabetes, diet and exercise regimen is recommended to 
patients. Upon six weeks course of diet and exercise plan, patients will show improvement if 
there is any. If the patients fail to achieve near target blood glucose levels from diet and exercise 
regiment, then pharmacotherapy is added to diet and exercise plan. Pharmacotherapy includes 
oral anti diabetic drugs. Physicians must consider benefits of each drug against cost, 
contraindications, degree of glycemic-lowering needed, ease of compliance, duration of action, 
patient’s weight and patient’s lipid profiles.  
The sulphonylureas and biguanides are the most commonly prescribed categories of 
medications for oral anti diabetic therapy. They are safe, have better tolerability and superior 
pharmacodynamic effects. Sulfonyl ureas stimulate the release of insulin from the pancreatic 
islet cells via stimulation of receptors. Glipizide is one of the commonly prescribed anti diabetic 
drugs from short acting sulphonyl urea category. Short acting sulphonyl urea drugs have some 
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advantages compared to long acting sulphonyl urea drugs. Short acting sulphonyl ureas are more 
efficient in increasing meal-stimulated insulin secretion and have lower risk of hyperglycemia. 
Glipizide was synthesized chemically in 1971 and has excellent safety profile. Glipizide 
is an effective therapeutic agent for both first phase insulin secretion and for providing sustained 
stimulatory response during long term treatment. Blood glucose concentration starts to decrease 
within 30 min of ingestion of glipizide. Glipizide is 100 times more potent than tolbutamide. 
Glipizide has uniform, rapid absorption throughout the gastro intestinal tract. Peak plasma 
concentration of Glipizide is observed within 1-3h after single oral dose. Half life of Glipizide is 
2 to 4 h in both intravenous and oral administration. Glipizide has no plasma accumulation 
following repeated oral dosing. In spite of its clinical efficiency, Glipizide has poor patient 
compliance because of its multiple daily dosing. Thus, it is appropriate to formulate Glipizide in 
controlled release formulation. Glipizide is commercially available as controlled release 
formulation.  
Glipizide is a weakly acidic, water insoluble drug. It belongs to class II drugs of 
biological classification system (BCS). Class II drugs have poor solubility and high permeability. 
Commercial controlled release formulation of Glipizide uses osmotic drug delivery technology. 
Commercial controlled release formulation of Glipizide is a coated bilayer tablet (Push-pull 
system). One layer contains drug and the other layer contains osmogen and other ingredients 
required to push the drug through the laser drilled hole. The tablet is coated with cellulose 
acetate. Cellulose acetate is semi-permeable i.e., it is permeable only to water not for other 
substances. Upon water entry into the tablet through semi-permeable membrane, the osmogens 
dissolve and create osmotic pressure inside the tablet. Osmotic pressure drives the drug out of the 
tablet through the laser drilled delivery orifice. Osmotic drug delivery systems are difficult to 
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manufacture and they need special equipments for manufacturing. The objective of this work is 
to develop bioequivalent formulation of Glipizide to its commercial formulation, Glucotrol® XL. 
And, it is also of our interest to develop controlled release matrix formulation using carbopol as 
release controlling polymer and hot melt granulation technology. 
As mentioned in formulation development of propranolol hydrochloride, hot melt 
granulation technique is a versatile technique offering many formulation options. However, the 
excipients must be selected based on the properties of drug and the requirements of controlled 
release. Following section presents rationale for selection of binder and fillers in the formulation 
 
4.2. SELECTION OF FORMULATION COMPONENTS 
 
4.2.1. Selection of binder 
Glipizide is a poorly soluble weakly acidic drug. Glipizide has pH dependent solubility. 
Solubility of the glipizide is 0.078 mg/ml in pH 6.8 and it is virtually insoluble in pH 1.2. 
In hot melt granulation technique, waxy material is used as binder. Waxy binder can be either 
hydrophilic e.g. Gelucire with higher HLB value or hydrophobic e.g. waxes with lower HLB 
values. In this case, the objective is to formulation controlled release formulation of Glipizide 
that is bioequivalent to osmotic delivery system of Glipizide. Osmotic delivery system has 
constant release rate for 14 h. Therefore, the ingredients used in the formulation, must not 
interfere with the dissolution of the drug as it may result in formulation that will have very low 
release rate. If a hydrophobic wax is selected as binder in the formulation, then a dispersion of 
drug in the hydrophobic wax will be formed. This will hamper the water availability for the 
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dissolution of drug particles. Therefore, hydrophobic waxes must be avoided in the formulation. 
Gelucire 50/13, a hydrophilic wax, is selected as binder for the formulation. 
 
4.2.2. Selection of filler 
Glipizide is a low dose drug. It is administered in three doses of 2.5 mg, 5 mg and 10 mg. 
In this study, our objective is to develop bioequivalent formulation for 10 mg dose. However, it 
is difficult formulate such a low dose without a filler. Fillers are available in various choices. 
They are: (i) Water insoluble, non-swellable e.g. Dicalcium phosphate, (ii) Water insoluble, 
water swellable e.g. Microcrystalline cellulose, (iii) Water soluble, non-swellable e.g. Lactose 
monohydrate. As mentioned earlier, inclusion of water insoluble material will hamper the 
availability of water to the drug dissolution. In order to achieve complete drug release from a 
formulation containing poorly soluble drug, the excipients in the formulation should not interfere 
with the drug dissolution. Therefore, dicalcium phosphate is not a good choice for filler and 
either microcrystalline cellulose or lactose monohydrate can be selected as fillers.  
Microcrystalline cellulose is depolymerized cellulose and has tremendous water uptake 
capacity. Since microcrystalline cellulose promotes water influx into the system, the release 
controlling mechanism in matrix tablet will be ruined. Matrix systems control the drug release by 
modulating the water influx and controlling the drug efflux. Therefore, in order to compensate 
for water influx, higher polymer concentration will be needed. This will increase the cost of the 
delivery system. Hence, unless justified, microcrystalline cellulose is not a filler of choice. On 
contrary, lactose monohydrate is water soluble filler and it dissolves slowly in water. Lactose 
absorbs less water compared to microcrystalline cellulose however it does not impede the water 
influx into the system like dicalcium phosphate. As lactose dissolves, it creates pores in the 
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delivery system and these pores aid drug release. Since lactose dissolves slowly, the extent of 
pore creation does not ruin the controlled release properties of release controlling polymer. 
Therefore, lactose monohydrate is filler of choice for the formulation.  
 
4.3. MATERIALS AND METHODS 
 
4.3.1. Materials 
Glipizide, Carbopol 971P (Noveon, Cleveland, OH), Gelucire 50/13 (Gattefosse, 
Paramus, NJ), Lactose monohydrate (Foremost, Baraboo, WI), Microcrstalline cellulose (MCC) 
(Avicel® PH-101) (FMC corporation, Philadelphia, PA). 
 
4.3.2. Methods 
 
4.3.2.1. Preparation of tablets 
Hot melt granulation technique was used to prepare granules from the blend containing 
appropriate quantities of Glipizide, Carbopol 971P, filler and Gelucire 50/13.  Ingredients and 
composition of formulations are given in the Table 4.1 and Table 4.2 respectively. Ingredients 
of each formulation except the waxy binder were mixed for two minutes in the reverse mode at 
1500 rpm prior in a Robot-Coupe® high shear mixer-granulator (Robot-Coupe Inc., Jackson, 
MS). After blending, a circulating water bath was attached to the granulator bowl. Temperature 
of the bowl was monitored using a digital thermometer. Once the temperature of the bowl 
reached 60°C, waxy binder was added to the powder blend. Bowl temperature was kept at 60°C 
during granulation. Granulation was carried out in the reverse mode at 1500 rpm for 2 min. 
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Table 4.1. Ingredients of formulations for glipizide product development 
 
 
Batch code Filler Tablet weight Drug - polymer ratio Polymer-wax ratio 
L-1 Lactose 100 1::0.5 1::1 
L-2 Lactose 100 1::1 1::1 
L-3 Lactose 400 1::0.5 1::1 
L-4 Lactose 400 1::1 1::1 
M-1 Avicel 400 1::1 1::1 
M-2 Avicel 400 1::2 1::1 
M-3 Avicel 400 1::4 1::1 
M-4 Avicel 400 1::6 1::1 
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Table 4.2. Compositions of formulations for glipizide product development 
 
 
Batch code Drug (%) Carbopol (%) Gelucire (%) Filler (%) 
L-1 10.00 5.00 5.00 80.00 
L-2 10.00 10.00 10.00 70.00 
L-3 2.50 1.25 1.25 95.00 
L-4 2.50 2.50 2.50 92.50 
M-1 2.50 2.50 2.50 92.50 
M-2 2.50 5.00 5.00 87.50 
M-3 2.50 10.00 10.00 77.50 
M-4 2.50 15.00 15.00 67.50 
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The resulting granules were passed through a 20-mesh sieve to remove any coarse granules while 
they were still warm. The sieved granules were allowed to cool to room temperature. Tablets 
from aforementioned granules were prepared using an 18-station rotary tablet press equipped 
with 5/16” deep-concave punches and dies was used for tablet compression.  
 
4.3.2.2. Evaluation of in vitro dissolution 
Tablets were tested for its dissolution characteristics using USP apparatus II (paddle). 
Hydrochloric acid (0.1 N, 750 ml) was used as the dissolution media for the first 2 hours. Then, 
the pH of the dissolution media was adjusted to 6.8 using 250 ml of 1N tribasic phosphate 
solution. Drug dissolution from the tablets was determined at 37°C at 50 rpm. Drug release from 
the tablets was monitored using in situ fiber optic UV probes equipped with PDA (Photo diode 
array) detectors (PION, Inc., Woburn, MA). Estimation of the drug concentration in the 
dissolution media was based on single point calibration at 288 nm.  
 
4.4. RESULTS AND DISCUSSION 
 
4.4.1. Lactose based formulations 
Composition of formulations with lactose as filler is given in the Table 4.2. Formulations 
L – 1 and L -2 have 100 mg tablet weight. Both formulations contain different drug to polymer 
ration. While L – 1 contains 1:0.5 drug-polymer ratio, L – 2 contains 1:1 drug to polymer ratio. 
In vitro dissolution profiles of the formulations are presented in Figure 4.1. These 100 mg 
sustained release tablets containing lactose as filler had long lag time. Only less than 20% 
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Figure 4.1. Dissolution profiles of formulations containing lactose as filler† 
 
† Each data point represents average of three measurements. Standard deviation of three 
measurements is presented as error bars.  
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 drug was released from the tablets till 8 h. Then, the matrix started to disintegrate and dump the 
drug out. Within 12 – 14 h, the drug release from formulations was almost complete. This can be 
attributed to higher solubility of lactose monohydrate compared to drug solubility. In phosphate 
buffer, Lactose solubility is 148 µg/ml and the Glipizide solubility is 78 µg/ml. When dissolution 
media enters into the matrix, there is a competition between the lactose and glipizide. Since 
lactose has more solubility than glipizide, it dissolves faster than glipizide. This reduces the 
availability of dissolution media for the dissolution of glipizide hence dissolution of glipizide. As 
lactose continues to dissolve and leave the matrix, it creates pores that weaken the matrix 
structure. In addition, dissolution of lactose increases the osmotic gradient and with draws more 
dissolution media into the system. The continuous increase in osmotic pressure weakens the 
matrix and results in matrix disintegration and dose dumping after certain time (8 h). Thus, the 
100 mg formulations containing lactose as filler has two problems 
i. Insufficient availability of the dissolution media for drug dissolution in the initial period  
ii. Competitive reduction in drug dissolution.  
Although competitive reduction in drug dissolution can not be rectified due to the lactose’s 
higher solubility, dissolution media influx into the matrix can be increased. Increase is 
dissolution media influx will provide more dissolution media for dissolution of drug hence 
improve the drug release. Dissolution media influx can be increased by increasing the lactose 
content in the formulation. Therefore, the tablet weight was increased to 400 mg by increasing 
the lactose content in the formulations. However, for comparative purposes, the drug-polymer 
ratio is kept at constant level of 1: 0.5 and 1:1 drug-polymer ratio. 
Formulations L – 3 and L – 4 were 400 mg tablets containing drug – polymer ratio of 
1:0.5 and 1:1 respectively. In vitro dissolution profiles of formulations L – 3 and L – 4 are given 
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in Figure 4.1. As expected, 400 mg formulations containing more lactose released drug faster 
than 100 mg formulations. No lag period was observed in drug release in dissolution media PH 
6.8. However, the drug release was complete in less than 10 h. To be bioequivalent to osmotic 
system of glipizide, the matrix formulation must have controlled drug release for 14 h. Faster 
drug release from 400 mg lactose based formulations can be attributed to insufficient polymer 
content to control the drug release. Therefore, by increasing polymer content or decreasing 
lactose content, controlled release formulation of glipizide can be developed. And the filler 
content and polymer content can be optimized to yield bioequivalent formulation of glipizide. 
However, the controlled release from the formulation will be dependent on the controlling drug 
solubility based on dissolution media influx in to the matrix tablets. In in vivo conditions, 
composition, volume and pH of the gastric contents may change in fast and fed conditions. In 
such circumstances, the dissolution profile glipizide from lactose based formulation will also 
change. Therefore, the lactose based formulations are not robust. In addition, all formulations 
using lactose as filler had picking problems and low tablet hardness (3 to 4 kps for 400 mg 
tablets). Although it can be solved by addition of lubricants and glidants, no such attempts were 
made as the release profiles from lactose based formulation lack scope for further development.  
 
4.4.2. Microcrystalline cellulose based formulations 
Filler of 400 mg formulations was changed to microcrystalline cellulose from lactose 
monohydrate. Change of filler to microcrystalline cellulose yielded tablets with good hardness (9 
to 11 kps) and no picking or sticking problem was observed during compression. However, as 
expected, the drug release from microcrystalline cellulose based formulations was faster. This 
can be attributed to increase in dissolution media influx into the system caused by the presence 
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of microcrystalline cellulose. To control the influx of the dissolution media and efflux of the 
drug, polymer content was increased and four formulations were prepared. The composition of 
formulations is given in Table 4.2 and their release profiles are given in Figure 4.2. 
Formulations M 1 to M 4 have differences in drug-polymer ratio. They had drug-polymer ratio of 
1:1, 1:2, 1:3 and 1:6. Increase in drug – polymer ratio reduced the release rate. Formulation M4 
containing 1:6 drug – polymer ratio had closest release profile to commercial formulation. 
Bioequivalence of the microcrystalline cellulose based formulations were checked using F-2 
values. F-2 values were calculated using following formula and drug release from commercial 
formulation as reference. 
 
}100])(11log{[50 5.02
1
2 ×−+= −
=
∑ ttn
t
t TRwn
f                           (Eq.5.1) 
 
Where n is the number of sampling time points used. In this study, n is equal to 10. Rt is the 
actual cumulative percentage of acetaminophen released from the beads at each of the selected n 
time points. Tt is the ANN model predicted cumulative percentage of acetaminophen released 
from the beads at each of the selected n time points. wt is the optional weight factor. In this 
study, wt is equal to 1. 
When the two profiles are identical, f2 = 100.  The f2 value is equal to 50 when an 
average difference of 10% between the dissolution profiles that are being compared, is observed 
at all time points used for the calculation of the f2 value. The FDA has set a public standard of f2 
value between 50 and 100 to indicate similarity between two dissolution profiles. A formulation 
is considered bioequivalent if the F2 values are above 50. 
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Figure 4.2. Dissolution profiles of formulations containing MCC as filler† 
 
† Each data point represents average of three measurements. Standard deviation of three 
measurements is presented as error bars.  
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 Based on this criterion, formulation M – 4 containing drug – polymer ratio of 1:6 is 
bioequivalent to commercial formulation. Although proven bioequivalent, formulation M – 4 had 
incomplete drug release. Average drug release of 79.49% was observed at the end of 16 h. 
Therefore, to maximize the drug release with out significantly changing F-2 value, artificial 
neural network model was developed and optimization of the formulation composition was done 
using genetic algorithm and artificial neural network model. Drug – polymer ratio of 
microcrystalline cellulose formulations and their F2 values are given in the Table 4.3. 
 
4.4.3. Formulation optimization 
 
4.4.3.1. Artificial neural network modeling (ANN) 
Artificial neural network modeling is an artificial intelligence based modeling tool. It 
uses similar techniques to that of normal human learning behavior. That is, initially the trend in 
the data is identified using a set of data called “training set” then the model is validated for 
further use. It is commonly used by pharmaceutical scientists for solving various problems. Drug 
release optimization is one of the challenging problems that will require ANN modeling.  
Artificial neural network modeling is a versatile modeling tool. Both linear and non-
linear functions can be modeled using ANN. ANN models contain three components; input 
layer, hidden layer and output layer. Input layer contains independent factors of the model and 
the output layer contains dependent variables of the model. Hidden layer comprises of 
mathematical transformations called neurons. Each neuron represents a mathematical 
transformation. Neurons connect input layer and output layer. Independent variables are 
mathematically transformed as they are connected with output layer through neurons.
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Table 4.3. F2 values of formulations M 1 to M 4 
 
 
Batch code Drug – polymer ratio F – 2 value 
M  - 1 1:1 19.59 
M – 2 1:2 22.84 
M – 3 1:4 33.66 
M – 4 1:6 52.16 
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After the mathematical transformation, the relationship between input factors and output 
loses logical meaning. Therefore, the ANN models have no statistical meaning hence sometimes 
they are called “black box”. However, the predictability of the ANN models is superior to 
conventional statistical models. The exceptional predictability of ANN models have been 
attributed to selection of appropriate mathematical transformations and input scaling functions of 
ANN modeling. When a set of input factors and output are presented to ANN model, the input 
factors are scaled down to reduce the dimension of input space. These scaling functions are 
called “squashing” functions and they convert the numerical values of inputs to symbols 
representing low and high ranges of the input. For example, if the one of the inputs of ANN 
model is 25, 40.60 and 75, then the range is fist computed and in this case it is 25 to 75. Low 
value of 25 is assigned a value of -1 and the high value of 75 is assigned +1 and the values in 
between take corresponding values in this scale. Squashing of inputs normalizes the inputs and 
reduces the dimension.  Following input scaling, the scaled inputs are transformed in hidden 
layers. Transformation of scaled input is done by mathematical functions. There are many 
mathematical functions that are used for transforming inputs and sigmoid transformation, 
tansigmoid transformation, log transformation are few popular transformation functions. 
Selection of mathematical function is dependent on the error distribution. That is, an appropriate 
input transformation is selected to minimize the error in the training set. The data presented to 
ANN model is generally segmented using random sampling in to three sets; training set, test set 
and validation set. Initially, the transformation functions are selected based on the input-output 
relationship in the test set and a random weight is added to the transformation functions. Then, 
output values are predicted using an equation containing these transformations and randomly 
generated weights. An error distribution is calculated from predicted values and actual output 
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values in the test set. Then this error function is minimized by adjusting weights and/or changing 
transformations. The modifications in weight and transformation functions are done till 
maximum minimization of error function is achieved. This process of adjusting weights and 
choosing transformation is called “training”. The training will stop once the error function 
reaches minimum value. After the training stops, the ANN model can be validated using an 
external validation set.  
ANN model training is similar to human brain’s learning. That is, the relationship pattern 
between inputs and outputs is studied from known examples (training set). However, ANN 
model use mathematical functions with no logical justification unlike human brain where 
relationship patterns are associated with logic. This difference in learning between human brain 
and ANN model has advantage and disadvantage. Advantage is the numerical accuracy in 
predictions which is higher than the human brain. Disadvantage is “overlearning”. Overlearning 
is a process of extended training leading to selection of wrong input-output relationship pattern. 
Overlearning happens when error in the data distribution “mislead” the ANN model to select 
wrong transformation functions. This will result in learning from error rather than true input-
output relationship. The outcome of “overlearning” is lack of generalization which is manifested 
as least training error and high error in predictions with validation set. In most of the softwares 
used for ANN model building, training schemes are tweaked to periodically consult with 
independent validation set to stop the training process in early stages of training before 
overlearning begins. One of the easiest tweaks in the training scheme to prevent overlearning is 
“leave-one-out” cross validation. In “leave-one-out” cross validation, test set is divided into test 
set and an internal validation set. While test set is used to adjust training weights, internal 
validation set is used to terminate the training process before the overlearning begins. This 
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process is continued by using validation set as part of training set and using another part of data 
as validation set. This is one of the effective means for preventing over learning.  
 
4.4.3.2. Formulation optimization using ANN 
Objective of current ANN model is to identify the formulation that can release drug 
completely. AI Triology® software program (Ward systems, Frederick, MD) was used for ANN 
model building. AI Triology® uses backpropagation training and generalized regression training 
algorithms. Earlier studies on selection of training algorithm for training indicate that generalized 
regression algorithm had better generalization than backpropagation algorithm. Therefore, only 
generalized regression algorithm was used for model development in this study. Following 
model development and leave one out cross validation, ANN model showing least prediction 
error was selected for formulation optimization. Genetic algorithm was used for formulation 
optimization. Drug release profile of commercial formulation was used as reference. Constraints 
were added on the later time points to support the optimization algorithm to find regions where 
results that can fulfill the objective of the current study i.e., to yield a formulation that can 
release the drug completely. Optimization based on ANN model yielded the formulation 
composition containing 11.25% carbopol with 2.5% drug loading and 400 mg tablets containing 
microcrystalline cellulose as filler. Figure 4.3 presents the comparison of predicted dissolution 
profiles of ANN predicted formulation and the actual dissolution profiles of the ANN predicted 
formulation. F – 2 values between these predicted and actual formulation was 74.34%. This 
confirms the validity of the ANN model.  
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Figure 4.3. Comparison of ANN predicted and actual dissolution profiles† 
 
† Each data point represents average of three measurements. Standard deviation of three 
measurements is presented as error bars.  
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4.4.3.3. Effect of compression force on the drug release 
Literature reports that the drug release from carbopol matrix is sensitive to the 
compression force. This is attributed to change in the interstitial space in higher compression 
force. Higher the compression forces lower the interstitial space between polymer particles in the 
tablet. This will boost the controlled release performance of the polymer. Thus it is of our 
interest to test the effect of compression force on the drug release of ANN optimized 
formulation. Therefore, 400 mg tablets containing 11.25% of carbopol and microcrystalline 
cellulose as filler were compressed at two more additional compression forces of 1 mT and 1.5 
mT. Although only marginal increase in tablet hardness was achieved, significant changes in the 
in vitro dissolution profile was observed when the compression force was increased to 1 mT 
from 0.5 mT.  However, there is less changes in the drug release was observed when the 
compression force was increased to 1.5 mT from 1 mT. Figure 4.4 presents the effect of 
compression force on drug release profiles of the ANN predicted formulation. Table 4.4 presents 
F-2 values of these formulations against commercial formulation. Formulation containing 
11.25% of carbopol and microcrystalline cellulose as filler and prepared with both 1 mT and 1.5 
mT were bioequivalent to commercial formulation. 
 
4.5. CONCLUSIONS 
Bioequivalent formulations of glipizide were prepared using carbopol – wax blends. 
Lactose based formulations either released drug quickly or had long lag time. Lactose based 
formulations had poor tablet hardness and picking problem during compression. Microcrystalline 
cellulose based formulations yielded tablets with better hardness compared to lactose based 
formulations and had no picking problem during compression. Drug release from 
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Figure 4.4. Effect of compression force on dissolution profiles† 
 
† Each data point represents average of three measurements. Standard deviation of three 
measurements is presented as error bars.  
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Table 4.4. F2 values of batches prepared using different compression forces 
 
 
Compression force F – 2 value Drug release at 16 h 
0.5 mT 41.42 96.41% 
1 mT 58.47 83.07% 
1.5 mT 50.89 79.65% 
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microcrystalline cellulose based formulations was proportional to the drug – polymer ratio. Drug 
release from microcrystalline cellulose based formulations was related to compression force used 
to compress the tablets. Increasing the compression force reduced the extent of drug release and 
yielded zero order release formulations.   
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Chapter 5: Non Destructive Prediction of Dissolution Profiles Using NIRS 
 
5.1. INTRODUCTION 
Near Infrared Spectroscopy (NIR) has been used in the pharmaceutical industry for both 
quality control and process monitoring at in-line, on-line and at-line locations to control the 
quality attributes of products and by-products. It is an attractive quality control tool because of 
its versatility, quickness and absence of sample preparation.  
Literature suggests NIR can be used in various stages of tablet dosage form manufacture. 
NIR can be used in raw material identification, determination of water content in raw materials, 
identification of impurities or isomeric forms of raw materials, monitoring blend uniformity in 
mixing operation, estimating granule size and density changes in granulation process, measuring 
the rate of drying in the drying operation, estimating hardness, drug content, disintegration and 
dissolution of tablets, monitoring coating thickness in coating operation etc.  
In spite of the availability of substantial evidence from literature on use of NIR in tablet 
manufacturing, measurement of dissolution from sustained release dosage form is an unexplored 
territory. Primary reason is that drug dissolution is a complex process dependent on many 
properties of the delivery system and dynamic changes occurring during the drug release. Drug 
dissolution rate depends on the type of dosage form (compressed/coated), solubility of the drug 
and interaction between drug and other excipients in tablet. NIR spectrum of a tablet contains 
sparse information about polymer characteristics, tablet hardness, water content, drug 
concentration etc. These properties can have a direct relationship with the rate of drug 
dissolution. However, the initial properties of tablets such as drug content, water content, 
hardness, density will change during the dissolution process. These changes are time and 
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concentration dependent. Thus, the challenge in modeling drug dissolution with near infrared 
spectrum is the lack of complete information about dissolution process per se in the spectrum. 
However, if these changes are directly related to the initial properties of the system, then a valid 
relationship must exist between NIR spectrum and dissolution profile. This relationship may be 
linear or nonlinear depending on drug release kinetics. If the drug release is independent of time 
(Zero order), then initial concentration of the ingredients determine rate of drug release and the 
rate of drug release remains constant till the end of dissolution period. In such circumstances 
(zero order release), the relationship between NIR spectrum and drug release profile might be 
linear. If however, the drug release rate changes with time, then NIR spectrum-drug release 
profile relationship could be non-linear or may have no correlation. 
Generally, drug release from sustained release matrix tablet is directly proportional to 
polymer concentration. However, polymer erosion, changes in drug concentration gradient, 
changes in drug diffusion path, changes in matrix integrity and tortousity can distort in the NIR 
spectrum-dissolution profile relationship, thus resulting in poor predictability of NIR models. 
Higuchi’s square root time dependent release kinetics is the most common nonlinear drug release 
pattern observed in sustained release hydrophilic matrix tablets. In some cases, part of the drug 
dissolution profile is linear and the other part is nonlinear. That is, drug release rate remains 
constant in one part of the dissolution profile and release rate varies in the other part of the 
dissolution profile. 
For modeling such complex relationships, multivariate regression models must estimate 
the spectral variability caused not only by the initial properties (hardness, thickness, moisture 
content, etc.) of the tablets, but also extract relevant information from the spectrum that has 
relationship with the drug dissolution from the tablets. For example, the initial drug release might 
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be related to tablet hardness, however, in the later stages, as polymer hydrates, initial tablet 
hardness may not have any relationship with drug release. Since physical properties of the tablets 
and chemical nature of polymer influence the drug release interactively, it is difficult to attribute 
the changes to a specific peak in NIR spectrum. Rather, the spectral variance in a region can 
have relationship and this region can only be identified during calibration model building. Such 
modeling tasks are computationally intensive. Thus, selection of appropriate algorithm to 
complete the task quickly with no compromise on predictability of the model is important. This 
poster presents a comparison of multivariate modeling algorithms such as Partial Least Square, 
Support Vector Machines (SVM) and K-Nearest Neighbors (KNN).  Partial Least Square (PLS) 
technique is well known in the pharmaceutical world and most commonly used NIR modeling 
technique. The other two techniques are uncommon in pharmaceutical industries, but have been 
used in food, agriculture, and business intelligence sectors. SVM and KNN are useful in special 
circumstances where non-linear, multivariate predictor-response relationship cannot be 
effectively modeled using PLS. This poster presents a comparison of prediction power of these 
three algorithms to estimate drug dissolution from sustained release matrix tablets containing 
propranolol hydrochloride.  
 
5.2. MATERIALS AND METHODS 
 
 
5.2.1. Materials 
 
 
Propranolol hydrochloride, Carbopol 971P NF (Noveon Inc.,Cleveland, OH), Eudragit L 
100 – 55 (Degussa Rohm Pharma Polymers, Piscataway, NJ), glyeryl monostearate (Stepan, 
Northfield, IL), Gelucire 50/13 (Gattefosse corporation, Paramus, NJ). 
 122
5.2.2. Methods 
 
 
5.2.2.1. Granulation 
Hot melt granulation technique was used to prepare granules from the blend containing 
appropriate quantities of propranolol HCl, Carbopol 971P, Eudragit L-100-55, glyceryl 
monostearate (GMS) and Gelucire 50/13.  A total of fifteen formulations were prepared by 
changing the composition of the aforementioned ingredients. Compositions of formulations are 
given in Table 5.1.  The batch size of each formulation was 300 g. A blend of waxy binder was 
prepared by melting GMS and Gelucire 50/13 at 60°C.  The molten mass was mixed thoroughly 
and poured on a metal tray, and allowed to cool to room temperature. The resulting waxy sheet 
was cut into small size flakes, which were then used as a waxy binder for the hot melt 
granulation technique. 
  Ingredients of each formulation except the waxy binder were mixed for two minutes in 
the reverse mode at 1500 rpm prior in a high shear mixer-granulator (Robot-Coupe® Inc., 
Jackson, MS). After blending, a circulating water bath was attached to the granulator bowl. 
Temperature of the bowl was monitored using a digital thermometer. Once the temperature of 
the bowl reached 60°C, waxy binder was added to the powder blend. Bowl temperature was kept 
at 60°C during granulation. Granulation was carried out in the reverse mode at 1500 rpm for 2 
min. The resulting granules were passed through a 20-mesh sieve to remove any coarse granules 
while they were still warm. The sieved granules were allowed to cool to room temperature.  
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Table 5.1. Composition of formulations  
 
 
Formulation† 
Code 
Glyceryl 
monostearate 
(%) 
Gelucire® 
50/13 
(%) 
Carbopol® 
971 P 
(%) 
Eudragit® 
L-100-55 
(%) 
Di-Tab® 
(%) 
PD-1 7.5 2.5 5 0 85 
PD-2 7.5 2.5 5 20 65 
PD-3 7.5 2.5 10 10 70 
PD-4 7.5 2.5 15 0 75 
PD-5 7.5 2.5 15 20 55 
PD-6 5 5 5 10 75 
PD-7 5 5 10 0 80 
PD-8 5 5 10 10 70 
PD-9 5 5 10 20 60 
PD-10 5 5 15 10 65 
PD-11 2.5 7.5 5 0 85 
PD-12 2.5 7.5 5 20 65 
PD-13 2.5 7.5 10 10 70 
PD-14 2.5 7.5 15 0 75 
PD-15 2.5 7.5 15 20 55 
 
† 400 mg tablets containing 80 mg of propranolol hydrochloride were compressed at two 
compression forces - 0.6 mT and 1.2 mT. 
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 5.2.2.2. Tabletting 
Tablets weighing 400 mg and containing 80 mg of propranolol HCl were prepared by 
compressing the aforementioned granules. An 18-station rotary tablet press equipped with 3/8” 
flat-faced punches and dies was used for tablet compression. Each formulation was compressed 
at two compression forces, 0.6 mT and 1.2 mT.  A total of fifteen formulations, each compressed 
at two different compression forces yielded 30 batches of tablets. Three tablets from each batch 
were randomly selected for NIR measurements.  
 
5.2.2.3. NIR spectroscopy 
NIR spectrum (from 400 nm to 2500 nm) of each tablet was taken from both sides using 
the Rapid Content Analyzer (Foss NIRSystems, Silver Spring, MD) in the reflectance mode. 
Constant spot size of light impingement of 9.25 mm was used for spectral measurements of all 
batches.  Thirty two co-added scans were taken for each tablet to improve the signal-to-noise 
ratio, and they constitute one spectrum. Unprocessed NIR spectrum was exported to Microsoft-
Excel®. The unprocessed spectrum for each tablet contained 4200 absorbance values, each taken 
at 0.5 nanometer gaps in the range of 400 nm to 2500 nm.  
 
5.2.2.4. In vitro dissolution study 
Following NIR spectral measurement, each tablet was tested for its dissolution 
characteristics using USP apparatus II (paddle). Hydrochloric acid (0.1 N, 750 ml) was used as 
the dissolution media for the first 2 hours. Then, the pH of the dissolution media was adjusted to 
6.8 using 250 ml of 1N tribasic phosphate solution. Drug dissolution from the tablets was 
determined at 37°C at 50 rpm. Drug release from the tablets was monitored using in situ fiber 
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optic UV probes equipped with PDA (Photo diode array) detectors (PION, Inc., Woburn, MA). 
Estimation of the drug concentration in the dissolution media was based on single point 
calibration at 288 nm. Drug dissolution profiles of all batches were calculated based on the UV 
absorbance, theoretical drug content, and volume of the dissolution media using Indigo® 
software (PION, Inc., Woburn, MA).  
 
5.2.2.5. Modeling 
Statistical models for correlating the NIR spectrum of 30 batches and their dissolution 
profiles were developed using STATISTICA® QC&Text miner (Statsoft, Tulsa, OK). Three 
regression modeling techniques such as PLS (Partial Least Square), SVM (support vector 
machine) and KNN (K-nearest neighbors) regression were used for screening purposes.  
For selection of the best algorithm, regression coefficient of the observed versus 
predicted values were used. The best algorithm should have a high regression coefficient. The 
best algorithm was then used for building prediction models and validation. NIR spectral data 
from Formulation 13 were used as the validation set and hence they were not used in the while 
building the calibration model. Thus, calibration models were built using the remaining 14 
formulations. These 14 formulations were randomly sampled and divided into 2 sets, namely 
training set (75%), and test set (25%). Calibration models were built and optimized using the V-
fold cross validation protocol. In the V-fold cross-validation, repeated (v) random samples are 
drawn from the training and test sets, and the respective model is then applied to compute the 
predicted values. A regression coefficient of 0.90 for calibration models was used as the 
predefined selection criteria for algorithm selection.  
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5.3. RESULTS AND DISCUSSION 
 
5.3.1. Algorithm screening 
 
5.3.1.1. PLS modeling 
In conventional PLS modeling, calibration model is built to correlate spectral data with 
one output. However, dissolution profile is a repeated measure data, i.e., measurement of drug 
released from a single tablet over time. Owing to constraints of the PLS modeling, the entire 
dissolution profile cannot be modeled with one PLS model. Thus, for algorithm screening 
purposes, three calibration models were built to correlate the NIR spectrum and drug released at 
2 h, 12 h and 24 h respectively. The models for predicting the amount of drug dissolved at 2 h, 
12 h and 24 h were named Y-2, Y-12 and Y-24 respectively. Regression coefficients of Y-2, Y-
12 and Y-24 were 0.839, 0.853 and 0.871 respectively indicating that only 83.9%, 85.3% and 
87.1% of variance in the dissolution profiles were explained by these models. Y-2, Y-12 and Y-
24 models included 8, 5 and 8 latent vectors respectively. Number of latent vectors was selected 
based on the requirement of vectors required to explain 99.5% of variance observed in the data 
set.  
Initially, selection of number of latent vector for global PLS model (model including 
entire spectrum) was based on cross-validation. Then, this number was optimized by screening 
different regions of spectum having maximum correlation with the response (amount of drug 
dissolved). This was done to improve the predictability of the model as this procedure removes 
noisy regions from model input.  
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NIR spectrum as mentioned earlier is a multivariate spectrum. Spectral noise and 
irrelevant information (unrelated to the response) in the spectrum can reduce the predictability of 
the calibration model. These effects can be removed from the spectrum by scanning the spectrum 
in predefined windows (wave length ranges). For example, the entire spectrum in the range of 
400 to 2500 nm (4200 absorbance readings) can be divided in to 20 windows each with 210 
absorbance readings. Selection of window size depends on the complexity of the predictor-
response relationship. Complex relationships might demand multiple windows be combined for 
final prediction models. 20 windows is generally an optimum setting for screening as suggested 
by the literature. PLS models built using a region of wavelength of the entire spectrum (window) 
are local models, however, containing maximum information about the response of interest. 
Interestingly, Y-2, Y-12, Y-24 prediction models had the following overlapping window regions: 
2200 to 2394.5 nm for Y-2, 2185 to 2289.5 nm for Y-12, 2185 to 2289.5 nm for Y-24.  In NIR 
spectrum, spectral region starting from 2200 nm has characteristic bands for –CH, -CH2 and –
CH3 groups. This could be attributed to polymers in the system. Release controlling polymers in 
the tablets used in this study were Carbopol and Eudragit. These two are acrylic acid derivatives. 
Carbopol is prepared by crosslinking acrylic acid monomer CH2CH(COOH) using allyl sucrose. 
Thus, spectral characteristics indicate a relationship between polymer content and drug release. 
However, the models did not have enough predictive power as judged by the pre-defined 
selection criteria. This could be attributed to limitations of the PLS modeling algorithm. PLS 
assumes linear relationship between predictors and response. As described earlier, linearity in the 
spectrum-dissolution profile can be distorted due to many factors. Thus, models that can account 
for nonlinearity in the spectrum-dissolution profile relationship could perform better. Hence, 
Support Vector Machine/Support Vector Regression algorithm was tested.  
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For, literature provides evidence for model development using support vector machines where 
nonlinearity in predictor-response relationship had ill-influence on model predictability. 
 
5.3.1.2. SVM modeling 
 
5.3.1.2.1. Theory 
Support vector machines (SVM) are based on concept of hyperplanes and decision 
boundaries. SVM algorithm maps the predictor variables and isolates them in hyper planes. For 
segregating (mapping) the predictor variables, decision boundaries are used in SVM. SVM was 
initially developed for classification tasks. In a simple classification task, assume that two 
objects with different qualities (e.g. blue and red) are present in a two dimensional plane (e.g. a 
flat surface). Geometrically defined place where the objects are present is called input space. To 
separate them, we must find the boundary line that can separate these two objects in the input 
space. This is analogous to drawing a line in a two dimensional plane to separate the blue and red 
objects. The process of drawing a decision line to separate objects in a hyper dimensional plane 
is called mapping. If a straight line is used for input mapping, then the line is called linear 
classifier. This forms the basis for statistical learning algorithms. This simple learning algorithm 
does not have enough power to explain multidimensional data (spectra data set) due to the data 
dimensionality, complexity, data density and colinearity characteristics. These difficult learning 
tasks are effectively handled by kernel learning algorithms such as SVM, multiple layer 
perceptron, etc.  
In SVM, decision boundaries, instead of decision lines (used in linear regression), are 
used for input mapping. For classification task in a multidimensional space, it is ideal to select a 
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hyper plane (decision line with boundaries) that correctly classifies the data, i.e., with a 
maximum distance to dissimilar objects. This distance between dissimilar objects is called a 
margin. Ideally, maximum margin must be achieved to facilitate accurate classification of a new 
data set. Thus, in a model training session, we must identify the hyperplane for separation of 
objects and maximizing the margin. Once identified and optimized, such hyperplanes are called 
maximum-margin hyperplanes or decision boundaries or optimal hyperplanes. Training set 
vectors that are close to the optimal hyperplanes are called support vectors. Optimal hyperplane 
provides probabilistic test error that is minimized when the margin is maximized.  
Before mapping, predictors are spread in input space (multidimensional ill-defined 
hypothetical space). After mapping with decision boundaries, the SVM algorithm converts the 
input space into feature space (well defined space with less dimensions compared to input 
space). This process is known as dimensionality reduction. This is a common concept in 
Machine Learning Theory. Dimensionality reduction improves generalization and reduces 
computational burden.  
In order to learn nonlinear predictor-response relationship using linear machines, the 
machine learning theory suggests usage of fixed non-linear mapping transforms that project data 
into a feature space.  Then a linear machine is used to classify them in the feature space. 
However, such tasks are computationally intensive. Computational burden of such task can be 
reduced using kernels. Kernals are mathematical functions that transform data implicitly (in 
input space itself) into a feature space and train a linear machine in input space. Thus, concept of 
kernels is pivotal in machine learning algorithms, and SVM is one of the machine learning 
algorithms. Four types of kernels are commonly used in SVM regression: linear, polynomial, 
radial basis function and sigmoid.  
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In SVM regression, a non-linear function is learned by a linear learning machine in a kernel-
induced feature space, while the capacity of the system is controlled by a parameter that does not 
depend on the dimensionality of the space. In any regression technique, a relationship between 
predictors and responses is assumed and expressed by a function and noise term.  
 
y = f(x) + noise                                                                                                        (Eq. 5.1) 
 
Now, the task is to find a functional form for f that can correctly predict new cases that 
the SVM has not been presented with during training. This is achieved by training the SVM 
model using training set and optimizing the error function and decision boundaries. The 
functional form of predictor-response relationship in SVM regression includes kernels, slack 
variables and weight vectors. Kernels are used for feature mapping and slack variables are used 
for defining geometrical margins of decision boundaries to improve generalization. Slack 
variables are the measure of error on training data points. Hence, selection of appropriate kernel 
and optimization of training parameters yield functional form of predictor-response relationship. 
Parameters in the functions are optimized using cross-validation during model training. Cross 
validation prevents “over learning” of the model. “Over learning” is the process by which the 
accuracy of trend identification is hampered by error present in the data. “Over learning” 
significantly affects the predictability of the model. Model may continuously over predict or 
under predict when “over learning” happens during model building. “Over learning” can be 
prevented using cross validation during training process.  
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5.3.1.2.2. Results 
SVM models for Y-2, Y-12, and Y-24 were developed with linear, polynomial and radial 
basis function kernels. Degree of polynomials was optimized for each model. Polynomial degree 
of 2 was optimal for the Y-2, Y-12 and Y-24 models as increase in polynomial degree did not 
provide any improvement in regression coefficients. Regression coefficients for Y-2 models with 
linear, polynomial and RBF kernels were 0.814, 0.710 and 0.773 respectively. Regression 
coefficients for Y-12 models with linear, polynomial and RBF kernels were 0.805, 0.704 and 
0.824 respectively.  Regression coefficients for Y-24 models were 0.790, 0.659 and 0.783. It can 
be inferred that SVM based on linear and RBF kernels had better explanatory power than models 
with polynomial kernel. However, the regression coefficients of models with linear and RBF 
kernels were lower than that of the PLS models. This implies that in spite of their sophisticated 
kernel based input mapping principle, SVM regression failed to offer better predictability than 
the PLS models. This could be attributed to predictor variance distribution. PLS model had 
specific predictor regions (windows) as model input. This region had maximum correlation with 
out puts; hence prediction errors caused by noisy inputs were eliminated. However, SVM uses 
the entire spectrum for modeling. Owing to “Garbage in-Garbage out” modeling principle, when 
noisy variables having little or no correlation with outputs are used as predictors, the model 
predictability is less. Thus predictability can be improved by selecting a spectral region that has 
maximum correlation with the cumulative amount of drug release. In addition, default training 
parameters were used for model training in this study. If the training parameters are optimized 
for each kernel type, then predictability could improve. Based on better predictability of linear 
kernels, it can be inferred that the predictors have valid linear relationship with responses. This 
means, the drug release (response) has a linear relationship with variance observed in the NIR 
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spectrum (predictor). If the variance in the NIR spectrum is directly related to the concentration 
of the polymers and excipients, then the drug release is directly related to polymer and excipient 
concentration.  
 
5.3.1.3. KNN modeling 
 
5.3.1.3.1. Theory 
K-Nearest neighbor (KNN) models are based on combination of local models. This 
means that the statistical analysis for the whole data set is split into local analyses and then 
combined. Predictors and responses of the training set are sampled and distance function is 
introduced between predictors. This distance function defines each predictor value. Then a 
neighborhood is formed by the predictors that are close to one another in terms of the distance 
between predictor values. In KNN, response from an unknown predictor is calculated by using 
the group of predictor values (neighborhood) that are close to the unknown predictor value. Thus 
predictability of the KNN model depends on the K value that defines number of elements in each 
neighborhood. Once the neighborhood of the unknown predictor value is identified, the predicted 
response will be the arithmetic mean response value of responses of predictor values in the 
neighborhood. KNN model fits data closely which might lead to overfitting, i.e., poor 
predictability caused by lack of generalization of the calibration model. Thus, distance function 
and cardinality of the neighborhood (K) must be carefully selected for building models with 
better predictability. K value is an indicator of adoptability of the model. Higher the K value, 
poorer the predictability. If the K value is small, then the model lacks generalization power to 
predict new cases. Optimal K value can be selected using V-fold cross-validation.  In V-fold 
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cross-validation, the number of folds (subsets of training data) is defined. For example, if the 
data is set to be divided into 10 folds, 10 subsets are created using random sampling. Then, 9 
subsets (number of folds minus one) will be used for training, and the unused set serves as the 
internal validation set. Prediction error of the model developed using 9 subsets, for the internal 
validation set is monitored to stop the training process. In the beginning of the training, the 
prediction error decreases as an appropriate K value is achieved. Then, if the K value continues 
to increase, the prediction error also starts to increase, thus indicating data overfitting. The 
training is terminated when the prediction error starts to increase, and the K value required for 
least prediction error is selected as the optimal K value. This process is repeated by swapping the 
internal validation set from one training subset. Thus, in the second iteration, a new internal 
validation serves to prevent overfitting. Once all the training subsets have served as internal 
validation sets, the training error is calculated by averaging errors observed in each iteration. 
 
5.3.1.3.2. Results 
KNN models were developed using four different types of distance measures, namely 
Euclidean, Euclidean squared, Cityblock and Chebychev. Numbers of nearest neighbors were 
optimized using V-fold cross-validation for each distance measure. Cityblock distance measure 
and three nearest neighbors were identified as the best distance training settings in terms of 
predictability.  Regression coefficients for Y-2, Y-12 and Y-24 models were 0.972, 0.964 and 
0.979. These regression values satisfied pre-set selection criteria of 0.9 for prediction models. 
Thus, KNN algorithm was used to model the drug dissolution profile, i.e., amount of drug 
released at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, 14 h, 16 h, 18 h, 20 h, 22 h and 24 h. The KNN 
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algorithm can handle multiple outputs. Thus, only one model was with Cityblock distance 
measure and three nearest neighbors was developed. 
 
5.3.2. Model validation 
KNN model was developed for predicting the entire dissolution profile using Cityblock 
distance measure. Observed and predicted values for the dissolution data obtained from 
Formulation 13 for both low and high compression forces are given in Figure 5.1. and Figure 
5.2, respectively. The regression coefficients between observed and predicted values were 0.984 
and 0.981 for formulation 13 prepared at low and high compression forces respectively. 
 
5.4. CONCLUSION 
Dissolution profiles of propranolol hydrochloride from sustained release matrix tablets 
were predicted from NIR spectra of tablets. Selection of algorithm was important to achieve the 
best predictability. K-nearest neighbor algorithm had better predictability than partial least 
square and support vector machine algorithms. 
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Figure 5.1. Validation using formulation 13 prepared at 0.6 mT† 
 
† Each data point represents average of three measurements. Standard deviation of three 
measurements is presented as error bars.  
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Figure 5.2. Validation using formulation 13 prepared at 1.2 mT  
 
† Each data point represents average of three measurements. Standard deviation of three 
measurements is presented as error bars.  
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